Document:

<PAGE>

                                                                     EXHIBIT 4.1

THIS WARRANT AND THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED, SOLD,
ASSIGNED OR TRANSFERRED, IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
UNDER SAID ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION UNDER SAID ACT IS NOT
REQUIRED.

                                                                 Warrant No. -__

                          COMMON STOCK PURCHASE WARRANT

               To Purchase ____________ Shares of Common Stock of

                         SPECTRUM PHARMACEUTICALS, INC.

      THIS IS TO CERTIFY THAT _______________, or registered assigns (the
"Holder"), is entitled, during the Exercise Period (as hereinafter defined), to
purchase from Spectrum Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), the Warrant Stock (as hereinafter defined and subject to adjustment
as provided herein), in whole or in part, at a purchase price of $10.00 per
share, all on and subject to the terms and conditions hereinafter set forth.

      1. Definitions. As used in this Warrant, the following terms have the
respective meanings set forth below:

      "Affiliate" means any person or entity that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under
common control with a person or entity, as such terms are used in and construed
under Rule 144 under the Securities Act. With respect to a Holder of Warrants,
any investment fund or managed account that is managed on a discretionary basis
by the same investment manager as such Holder will be deemed to be an Affiliate
of such Holder.

      "Appraised Value" means, in respect of any share of Common Stock on any
date herein specified, the fair saleable value of such share of Common Stock
(determined without giving effect to the discount for (i) a minority interest or
(ii) any lack of liquidity of the Common Stock or to the fact that the Company
may have no class of equity registered under the Exchange Act) as of the last
day of the most recent fiscal month ending prior to such date specified, based
on the value of the Company on a fully-diluted basis, as determined by a
nationally recognized investment banking firm selected by the Company's Board of
Directors and having no prior relationship with the Company.

      "Business Day" means any day except Saturday, Sunday and any day which
shall be a legal holiday or a day on which banking institutions in the State of
California generally are authorized or required by law or other government
actions to close.

<PAGE>

      "Change of Control" means the (i) acquisition by an individual or legal
entity or group (as set forth in Section 13(d) of the Exchange Act) of more than
one-half of the voting rights or equity interests in the Company; or (ii) sale,
conveyance, or other disposition of all or substantially all of the assets,
property or business of the Company or the merger into or consolidation with any
other corporation (other than a wholly owned subsidiary corporation) or
effectuation of any transaction or series of related transactions where holders
of the Company's voting securities prior to such transaction or series of
transactions fail to continue to hold at least 50% of the voting power of the
Company (or, if other than the Company, the successor or acquiring entity)
immediately following such transaction.

      "Closing Date" means April 21, 2004.

      "Commission" means the Securities and Exchange Commission or any other
federal agency then administering the Securities Act and other federal
securities laws.

      "Common Stock" means (except where the context otherwise indicates) the
Common Stock, $0.001 par value per share, of the Company as constituted on the
Closing Date, and any capital stock into which such Common Stock may thereafter
be changed or converted, and shall also include (i) capital stock of the Company
of any other class (regardless of how denominated) issued to the holders of
shares of Common Stock upon any reclassification thereof which is also not
preferred as to dividends or assets on liquidation over any other class of stock
of the Company and which is not subject to redemption and (ii) shares of common
stock of any successor or acquiring corporation received by or distributed to
the holders of Common Stock of the Company in the circumstances contemplated by
Section 4.3.

      "Current Market Price" means, in respect of any share of Common Stock on
any date herein specified,

      (1) if there shall not then be a public market for the Common Stock, the
higher of

            (a) the book value per share of Common Stock at such date, and

            (b) the Appraised Value per share of Common Stock at such date,

      or

      (2) if there shall then be a public market for the Common Stock, the
average of the daily market prices for the five (5) consecutive trading days
immediately preceding such date. The daily market price for each such trading
day shall be (i) the closing bid price on such day on the principal stock
exchange (including the NASDAQ Stock Market) on which such Common Stock is then
listed or admitted to trading, or quoted, as applicable, (ii) if no sale takes
place on such day on any such exchange, the last reported closing bid price on
such day as officially quoted on any such exchange (including the NASDAQ Stock
Market), (iii) if the Common Stock is not then listed or admitted to trading on
any stock exchange, the last reported closing bid price on such day in the
over-the-counter market, as furnished by the National Association of Securities
Dealers Automatic Quotation System or the National Quotation Bureau, Inc., (iv)
if neither such corporation at the time is engaged in the business of reporting
such prices, as furnished by any similar firm then engaged in such business, or
(v) if there is no such firm, as

                                       2
<PAGE>

furnished by any member of the NASD selected mutually by the holder of this
Warrant and the Company or, if they cannot agree upon such selection, as
selected by two such members of the NASD, one of which shall be selected by
holder of this Warrant and one of which shall be selected by the Company.

      "Current Warrant Price" means, in respect of a share of Common Stock at
any date herein specified, the price at which a share of Common Stock may be
purchased pursuant to this Warrant on such date. Unless and until the Current
Warrant Price is adjusted pursuant to the terms herein, the initial Current
Warrant Price shall be $10.00 per share of Common Stock.

      "Exchange Act" means the Securities Exchange Act of 1934, as amended, or
any similar federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect from time to time.

      "Exercise Period" means the period during which this Warrant is
exercisable pursuant to Section 2.1.

      "Expiration Date" means April 20, 2009.

      "GAAP" means generally accepted accounting principles in the United States
of America as from time to time in effect.

      "NASD" means the National Association of Securities Dealers, Inc., or any
successor corporation thereto.

      "Other Property" has the meaning set forth in Section 4.3.

      "Person" means any individual, sole proprietorship, partnership, joint
venture, trust, incorporated organization, association, corporation, limited
liability company, institution, public benefit corporation, entity or government
(whether federal, state, county, city, municipal or otherwise, including,
without limitation, any instrumentality, division, agency, body or department
thereof).

      "Purchase Agreement" means that certain Common Stock and Warrant Purchase
Agreement dated as of April 20, 2004 among the Company and the other parties
named therein, pursuant to which this Warrant was originally issued.

      "Restricted Common Stock" means shares of Common Stock which are, or which
upon their issuance upon the exercise of any Warrant would be required to be,
evidenced by a certificate bearing the restrictive legend set forth in Section
3.2.

      "Securities Act" means the Securities Act of 1933, as amended, or any
similar federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.

      "Trading Day" means any day on which the primary market on which shares of
Common Stock are listed is open for trading.

                                       3
<PAGE>

      "Transfer" means any disposition of any Warrant or Warrant Stock or of any
interest in either thereof, which would constitute a sale thereof within the
meaning of the Securities Act.

      "Warrants" means this Warrant and all warrants issued upon transfer,
division or combination of, or in substitution for, any thereof. All Warrants
shall at all times be identical as to terms and conditions and date, except as
to the number of shares of Common Stock for which they may be exercised.

      "Warrant Price" means an amount equal to (i) the number of shares of
Common Stock being purchased upon exercise of this Warrant pursuant to Section
2.1, multiplied by (ii) the Current Warrant Price.

      "Warrant Stock" means the ____________ shares of Common Stock to be
purchased upon the exercise hereof, subject to adjustment as provided herein.

      2. Exercise of Warrant.

      2.1. Manner of Exercise. From and after the first anniversary of the
Closing Date, and until 5:00 P.M., New York time, on the Expiration Date (the
"Exercise Period"), the Holder may exercise this Warrant, on any Business Day,
for all or any part of the number of shares of Warrant Stock purchasable
hereunder.

      In order to exercise this Warrant, in whole or in part, the Holder shall
deliver to the Company at its principal office or at the office or agency
designated by the Company as described in Section 10, (i) a written notice of
Holder's election to exercise this Warrant, which notice shall specify the
number of shares of Warrant Stock to be purchased, and which notice shall be
substantially in the form of the subscription form appearing at the end of this
Warrant as Exhibit A, duly executed by the Holder or its agent or attorney, (ii)
an investment representation letter in form and substance acceptable to the
Company and substantially in the form attached as Exhibit C executed by the
Holder, (iii) payment of the Warrant Price as provided herein and (iv) this
Warrant. Upon receipt thereof, the Company shall, as promptly as practicable,
and in any event within three Business Days thereafter, execute or cause to be
executed and deliver or cause to be delivered to the Holder a certificate or
certificates representing the aggregate number of full shares of Warrant Stock
issuable upon such exercise, together with cash in lieu of any fraction of a
share, as hereinafter provided. The stock certificate or certificates so
delivered shall be, to the extent possible, in such denomination or
denominations as the Holder shall request in the notice and shall be registered
in the name of the Holder or if permitted pursuant to the terms of this Warrant
such other name as shall be designated in the notice. This Warrant shall be
deemed to have been exercised and such certificate or certificates shall be
deemed to have been issued, and the Holder or any other Person so designated to
be named therein shall be deemed to have become a Holder of record of such
shares for all purposes, as of the date when the notice, together with the
payment of the Warrant Price and this Warrant, is received by the Company as
described above. If this Warrant shall have been exercised in part, the Company
shall, at the time of delivery of the certificate or certificates representing
Warrant Stock, deliver to the Holder a new Warrant evidencing the rights of the
Holder to purchase the unpurchased shares of Common Stock called for by this
Warrant, which new Warrant shall in all other respects be identical with this
Warrant, or at the request of the Holder, appropriate notation may be made on
this Warrant

                                       4
<PAGE>

and the same returned to the Holder.

      Payment of the Warrant Price may be made at the option of the Holder by:
(i) certified or official bank check payable to the order of the Company or (ii)
wire transfer of immediately available funds to the account of the Company. All
shares of Common Stock issuable upon the exercise of this Warrant pursuant to
the terms hereof shall be validly issued and, upon payment of the Warrant Price,
shall be fully paid and nonassessable and not subject to any preemptive rights.

      2.2. Fractional Shares. The Company shall not be required to issue a
fractional share of Common Stock upon exercise of any Warrant. As to any
fraction of a share which the Holder of one or more Warrants, the rights under
which are exercised in the same transaction, would otherwise be entitled to
purchase upon such exercise, the Company shall pay an amount in cash equal to
the Current Market Price per share of Common Stock on the date of exercise
multiplied by such fraction.

      2.3. Restrictions on Exercise Amount.

      Unless a Holder delivers to the Company irrevocable written notice prior
to the date of issuance hereof or sixty-one days prior to the effective date of
such notice that this Section 2.3 shall not apply to such Holder, the Holder may
not acquire a number of shares of Warrant Stock to the extent that, upon such
exercise, the number of shares of Common Stock then beneficially owned by such
holder and its Affiliates and any other persons or entities whose beneficial
ownership of Common Stock would be aggregated with the Holder's for purposes of
Section 13(d) of the Exchange Act (including shares held by any "group" of which
the holder is a member, but excluding shares beneficially owned by virtue of the
ownership of securities or rights to acquire securities that have limitations on
the right to convert, exercise or purchase similar to the limitation set forth
herein) exceeds 4.99% of the total number of shares of Common Stock of the
Company then issued and outstanding. For purposes hereof, "group" has the
meaning set forth in Section 13(d) of the Exchange Act and applicable
regulations of the Commission, and the percentage held by the holder shall be
determined in a manner consistent with the provisions of Section 13(d) of the
Exchange Act. The Company shall have no obligation to verify compliance with
this Section 2.3, other than to issue shares of Warrant Stock in accordance with
the exercise notice of each Holder. It shall be the responsibility of each
Holder to determine such Holder's compliance with this Section 2.3, and each
delivery of a notice of exercise by a Holder will constitute a representation by
such Holder that it has evaluated the limitation set forth in this paragraph and
determined, based on the most recent public filings by the Company with the
Commission, that the issuance of the full number of shares of Warrant Stock
requested in such notice of exercise is permitted under this paragraph.

      3. Transfer, Division and Combination.

      3.1. Transfer. This Warrant and the Warrant Stock issuable upon exercise
of this Warrant shall be freely transferable, subject to compliance with this
Section 3.1 and all applicable laws, including, but not limited to the
Securities Act. If, at the time of the surrender of this Warrant in connection
with any transfer of this Warrant or the resale of the Warrant Stock, this
Warrant or the Warrant Stock, as applicable, shall not be registered under the

                                       5
<PAGE>

Securities Act, the Company may require, as a condition of allowing such
transfer (i) that the Holder or transferee of this Warrant or the Warrant Stock
as the case may be, furnish to the Company a written opinion of counsel that is
reasonably acceptable to the Company to the effect that such transfer may be
made without registration under the Securities Act, (ii) that the Holder or
transferee execute and deliver to the Company an investment representation
letter in form and substance acceptable to the Company and substantially in the
form attached as Exhibit C hereto and (iii) that the transferee be an
"accredited investor" as defined in Rule 501(a) promulgated under the Securities
Act. Transfer of this Warrant and all rights hereunder, in whole or in part, in
accordance with the foregoing provisions, shall be registered on the books of
the Company to be maintained for such purpose, upon surrender of this Warrant at
the principal office of the Company referred to in Section 2.1 or the office or
agency designated by the Company pursuant to Section 10, together with a written
assignment of this Warrant substantially in the form of Exhibit B hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees and in the
denomination specified in such instrument of assignment, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Following a transfer that complies
with the requirements of this Section 3.1, the Warrant may be exercised by a new
Holder for the purchase of shares of Common Stock regardless of whether the
Company issued or registered a new Warrant on the books of the Company.

      3.2. Restrictive Legends. Each certificate for Warrant Stock initially
issued upon the exercise of this Warrant, and each certificate for Warrant Stock
issued to any subsequent transferee of any such certificate, unless, in each
case, such Warrant Stock is eligible for resale without registration pursuant to
Rule 144(k) under the Exchange Act, or has been sold pursuant to and in
compliance with Rule 144 or an effective registration statement under the
Securities Act, shall bear the following legend:

"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT UNLESS, IN THE OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH REGISTRATION IS NOT
REQUIRED."

            In addition, the legend set forth above shall be removed and the
Company shall issue a certificate without such legend to the holder of any
Warrant Stock upon which it is stamped, if, unless otherwise required by
applicable state securities laws, such Warrant Stock is eligible for resale
without registration pursuant to Rule 144(k) under the Exchange Act, or has been
sold pursuant to and in compliance with Rule 144 or an effective registration
statement filed under the Securities Act.

      3.3. Division and Combination; Expenses; Books. This Warrant may be
divided or combined with other Warrants upon presentation hereof at the
aforesaid office or agency of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with
Section 3.1 as to any transfer which may be involved in such division or
combination, the

                                       6
<PAGE>

Company shall execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with such notice.
The Company shall prepare, issue and deliver at its own expense the new Warrant
or Warrants under this Section 3. The Company agrees to maintain, at its
aforesaid office or agency, books for the registration and the registration of
transfer of the Warrants.

      4. Adjustments. The number of shares of Common Stock for which this
Warrant is exercisable, and the price at which such shares may be purchased upon
exercise of this Warrant, shall be subject to adjustment from time to time as
set forth in this Section 4. The Company shall give the Holder notice of any
event described below which requires an adjustment pursuant to this Section 4 in
accordance with Sections 5.1 and 5.2.

      4.1. Stock Dividends, Subdivisions and Combinations. If at any time while
this Warrant is outstanding the Company shall:

            (i) declare a dividend or make a distribution on its outstanding
shares of Common Stock payable in shares of Common Stock,

            (ii) subdivide its outstanding shares of Common Stock into a larger
number of shares of Common Stock, or

            (iii) combine its outstanding shares of Common Stock into a smaller
number of shares of Common Stock, then:

      (1) the number of shares of Common Stock acquirable upon exercise of this
Warrant immediately after the occurrence of any such event shall be adjusted to
equal the number of shares of Common Stock which a record holder of the same
number of shares of Common Stock that would have been acquirable under this
Warrant immediately prior to the record date for such dividend or distribution
or the effective date of such subdivision or combination would own or be
entitled to receive after such record date or the effective date of such
subdivision or combination, as applicable, and

      (2) the Current Warrant Price shall be adjusted to equal:

            (A) the Current Warrant Price in effect at the time of the record
      date for such dividend or distribution or of the effective date of such
      subdivision or combination, multiplied by the number of shares of Common
      Stock into which this Warrant is exercisable immediately prior to the
      adjustment, divided by

            (B) the number of shares of Common Stock into which this Warrant is
      exercisable immediately after such adjustment.

      Any adjustment made pursuant to clause (i) of this paragraph shall become
effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution, and any
adjustment pursuant to clauses (ii) or (iii) of this paragraph shall become
effective immediately after the effective date of such subdivision or
combination.

      4.2. Other Provisions Applicable to Adjustments. The following provisions
shall be

                                       7
<PAGE>

applicable to the making of adjustments of the number of shares of Common Stock
into which this Warrant is exercisable and the Current Warrant Price provided
for in Section 4:

            (a) When Adjustments to Be Made. The adjustments required by Section
4 shall be made whenever and as often as any specified event requiring an
adjustment shall occur, except that any that would otherwise be required may be
postponed (except in the case of a subdivision or combination of shares of the
Common Stock, as provided for in Section 4.1) up to, but not beyond the date of
exercise if such adjustment either by itself or with other adjustments not
previously made adds or subtracts less than 1% of the shares of Common Stock
into which this Warrant is exercisable immediately prior to the making of such
adjustment. Any adjustment representing a change of less than such minimum
amount (except as aforesaid) which is postponed shall be carried forward and
made as soon as such adjustment, together with other adjustments required by
this Section 4 and not previously made, would result in a minimum adjustment or
on the date of exercise. For the purpose of any adjustment, any specified event
shall be deemed to have occurred at the close of business on the date of its
occurrence.

            (b) Fractional Interests. In computing adjustments under this
Section 4, fractional interests in Common Stock shall be taken into account to
the nearest 1/100th of a share.

            (c) When Adjustment Not Required. If the Company undertakes a
transaction contemplated under this Section 4 and as a result takes a record of
the holders of its Common Stock for the purpose of entitling them to receive a
dividend or distribution or subscription or purchase rights or other benefits
contemplated under this Section 4 and shall, thereafter and before the
distribution to stockholders thereof, legally abandon its plan to pay or deliver
such dividend, distribution, subscription or purchase rights or other benefits
contemplated under this Section 4, then thereafter no adjustment shall be
required by reason of the taking of such record and any such adjustment
previously made in respect thereof shall be rescinded and annulled.

            (d) Escrow of Stock. If after any property becomes distributable
pursuant to Section 4 by reason of the taking of any record of the holders of
Common Stock, but prior to the occurrence of the event for which such record is
taken, a holder of this Warrant exercises the Warrant during such time, then
such holder shall continue to be entitled to receive any shares of Common Stock
issuable upon exercise hereunder by reason of such adjustment and such shares or
other property shall be held in escrow for the holder of this Warrant by the
Company to be issued to holder of this Warrant upon and to the extent that the
event actually takes place. Notwithstanding any other provision to the contrary
herein, if the event for which such record was taken fails to occur or is
rescinded, then such escrowed shares shall be canceled by the Company and
escrowed property returned to the Company.

      4.3. Reorganization, Reclassification, Merger, Consolidation or
Disposition of Assets.

            (a) If there shall occur a Change of Control during the period
beginning on the date hereof and ending on the Expiration Date, and, pursuant to
the terms of such Change of Control, shares of common stock of the successor or
acquiring corporation, or any cash, shares of stock or other securities or
property of any nature whatsoever (including warrants or other subscription or
purchase rights) in addition to or in lieu of common stock of the successor or
acquiring corporation ("Other Property"), are to be received by or distributed
to the holders of

                                       8
<PAGE>

Common Stock of the Company, then the Holder of this Warrant shall have the
right thereafter to receive, upon the exercise of the Warrant, the number of
shares of common stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and the Other Property receivable
upon or as a result of such Change of Control by a holder of the number of
shares of Common Stock into which this Warrant is exercisable immediately prior
to such event.

            (b) In case of any such Change of Control described in Section
4.3(a) above, the resulting, successor or acquiring entity (if not the Company)
and, if an entity different from the successor or acquiring entity, the entity
whose capital stock or assets the holders of the Common Stock are entitled to
receive as a result of such Change of Control, shall assume by written
instrument all of the obligations of this Warrant, subject to such modifications
as may be deemed appropriate (as determined by resolution of the Board of
Directors of the Company) in order to provide for adjustments of shares of the
Common Stock into which this Warrant is exercisable which shall be as nearly
equivalent as practicable to the adjustments provided for in Section 4. For
purposes of Section 4, common stock of the successor or acquiring corporation
shall include stock of such corporation of any class which is not preferred as
to dividends or assets on liquidation over any other class of stock of such
corporation and which is not subject to redemption and shall also include any
evidences of indebtedness, shares of stock or other securities which are
convertible into or exchangeable for any such stock, either immediately or upon
the arrival of a specified date or the happening of a specified event and any
warrants or other rights to subscribe for or purchase any such stock. The
foregoing provisions of this Section 4 shall similarly apply to successive
Change of Control transactions.

      4.4. Other Action Affecting Common Stock. In case at any time or from time
to time the Company shall take any action in respect of its Common Stock, other
than the payment of cash dividends payable out of earnings or earned surplus
legally available for the payment of dividends under the laws of the
jurisdiction of incorporation of the Company or any action described in Section
4, then, unless such action will not have a materially adverse effect upon the
rights of the holder of this Warrant, the number of shares of Common Stock or
other stock into which this Warrant is exercisable and/or the purchase price
thereof shall be adjusted in such manner as may be equitable in the
circumstances.

      4.5. Certain Limitations. Notwithstanding anything herein to the contrary,
the Company agrees not to enter into any transaction which, by reason of any
adjustment hereunder, would cause the Current Warrant Price to be less than the
par value per share of Common Stock.

      4.6. Stock Transfer Taxes. The issue of stock certificates upon exercise
of this Warrant shall be made without charge to the holder for any tax in
respect of such issue. The Company shall not, however, be required to pay any
tax which may be payable in respect of any transfer involved in the issue and
delivery of shares in any name other than that of the holder of this Warrant,
and the Company shall not be required to issue or deliver any such stock
certificate unless and until the person or persons requesting the issue thereof
shall have paid to the Company the amount of such tax or shall have established
to the satisfaction of the Company that such tax has been paid.

      5. Notices to Warrant Holders.

                                       9
<PAGE>

      5.1. Certificate as to Adjustments. Upon the occurrence of each adjustment
or readjustment of the Current Warrant Price, the Company, at its expense, shall
promptly compute such adjustment or readjustment in accordance with the terms
hereof and prepare and furnish to the Holder of this Warrant a certificate
setting forth such adjustment or readjustment and showing in detail the facts
upon which such adjustment or readjustment is based. The Company shall, upon the
written request at any time of the Holder of this Warrant, furnish or cause to
be furnished to such Holder a like certificate setting forth (i) such
adjustments and readjustments, (ii) the Current Warrant Price at the time in
effect and (iii) the number of shares of Common Stock and the amount, if any, or
other property which at the time would be received upon the exercise of Warrants
owned by such Holder.

      5.2. Notice of Corporate Action. If at any time:

            (a) the Company shall take a record of the holders of its Common
Stock for the purpose of entitling them to receive a dividend or other
distribution, or any right to subscribe for or purchase any evidences of its
indebtedness, any shares of stock of any class or any other securities or
property, or to receive any other right, or

            (b) there shall be any capital reorganization of the Company, any
reclassification or recapitalization of the capital stock of the Company or any
consolidation or merger of the Company with, or any sale, transfer or other
disposition of all or substantially all the property, assets or business of the
Company to, another corporation, or

            (c) there shall be a voluntary or involuntary dissolution,
liquidation or winding up of the Company; or

            (d) the Company shall cause the holders of its Common Stock to be
entitled to receive (i) any dividend or other distribution of cash, (ii) any
evidences of its indebtedness, or (iii) any shares of stock of any class or any
other securities or property or assets of any nature whatsoever (other than cash
or additional shares of Common Stock as provided in Section 4.1 hereof); or (iv)
any warrants or other rights to subscribe for or purchase any evidences of its
indebtedness, any shares of stock of any class or any other securities or
property or assets of any nature whatsoever;

then, in any one or more of such cases, the Company shall give to the Holder (i)
at least 15 days' prior written notice of the record date selected for such
dividend, distribution or right or for determining rights to vote in respect of
any such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition, dissolution, liquidation or winding up, and (ii) in the
case of any such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition, dissolution, liquidation or winding up, at least 15 days'
prior written notice of the date when the same shall take place. Such notice in
accordance with the foregoing clause also shall specify (i) the date on which
any such record is to be taken for the purpose of such dividend, distribution or
right, the date on which the holders of Common Stock shall be entitled to any
such dividend, distribution or right, and the amount and character thereof, and
(ii) the date on which any such reorganization, reclassification, merger,
consolidation, sale, transfer, disposition, dissolution, liquidation or winding
up is to take place and the time, if any such time is to be fixed, as of which
the holders of Common Stock shall be entitled to exchange their

                                       10
<PAGE>

shares of Common Stock for securities or other property deliverable upon such
reorganization, reclassification, merger, consolidation, sale, transfer,
disposition, dissolution, liquidation or winding up. Each such written notice
shall be sufficiently given if addressed to the Holder at the last address of
the Holder appearing on the books of the Company and delivered in accordance
with Section 12.2. The failure to give any notice required by this Section 5.2
shall not invalidate any such corporate action.

      5.3. No Rights as Stockholder. This Warrant does not entitle the Holder to
any voting or other rights as a stockholder of the Company prior to exercise and
payment for the Warrant Price in accordance with the terms hereof.

      6. No Impairment. The Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the
rights of the Holder against impairment. Without limiting the generality of the
foregoing, the Company will (a) not increase the par value of any shares of
Common Stock receivable upon the exercise of this Warrant above the amount
payable therefor upon such exercise immediately prior to such increase in par
value, (b) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant, and (c) use its best efforts to
obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof as may be necessary to enable the
Company to perform its obligations under this Warrant. Upon the request of the
Holder, the Company will at any time during the period this Warrant is
outstanding acknowledge in writing, in form satisfactory to the Holder, the
continuing validity of this Warrant and the obligations of the Company
hereunder.

      7. Reservation and Authorization of Common Stock; Registration With
Approval of Any Governmental Authority. From and after the Closing Date, the
Company shall at all times reserve and keep available for issue upon the
exercise of Warrants such number of its authorized but unissued shares of Common
Stock as will be sufficient to permit the exercise in full of all outstanding
Warrants (without regard to any ownership limitations provided in Section 2.3).
All shares of Common Stock which shall be so issuable, when issued upon exercise
of any Warrant and payment therefor in accordance with the terms of such
Warrant, shall be duly and validly issued and fully paid and nonassessable, and
not subject to preemptive rights. Before taking any action which would cause an
adjustment reducing the Current Warrant Price below the then par value, if any,
of the shares of Common Stock issuable upon exercise of the Warrants, the
Company shall take any corporate action which may be necessary in order that the
Company may validly and legally issue fully paid and non-assessable shares of
such Common Stock at such adjusted Current Warrant Price. Before taking any
action which would result in an adjustment in the number of shares of Common
Stock for which this Warrant is exercisable or in the Current Warrant Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof. If any shares of Common Stock required to be reserved for
issuance upon exercise of Warrants require registration or qualification with
any governmental authority

                                       11
<PAGE>

under any federal or state law before such shares may be so issued (other than
as a result of a prior or contemplated distribution by the Holder of this
Warrant), the Company will in good faith and as expeditiously as possible and at
its expense endeavor to cause such shares to be duly registered.

      8. Taking of Record; Stock and Warrant Transfer Books. In the case of all
dividends or other distributions by the Company to the holders of its Common
Stock with respect to which any provision of Section 4 refers to the taking of a
record of such holders, the Company will in each such case take such a record
and will take such record as of the close of business on a Business Day. The
Company will not at any time, except upon dissolution, liquidation or winding up
of the Company, close its stock transfer books or Warrant transfer books so as
to result in preventing or delaying the exercise or transfer of any Warrant.

      9. Loss or Mutilation. Upon receipt by the Company from the Holder of
evidence reasonably satisfactory to it of the ownership of and the loss, theft,
destruction or mutilation of this Warrant and indemnity or security reasonably
satisfactory to it and reimbursement to the Company of all reasonable expenses
incidental thereto and in case of mutilation upon surrender and cancellation
hereof, the Company will execute and deliver in lieu hereof a new Warrant of
like tenor to the Holder; provided, however, that in the case of mutilation, no
indemnity shall be required if this Warrant in identifiable form is surrendered
to the Company for cancellation.

      10. Office of the Company. As long as any of the Warrants remain
outstanding, the Company shall maintain an office or agency (which may be the
principal executive offices of the Company) where the Warrants may be presented
for exercise, registration of transfer, division or combination as provided in
this Warrant.

      11. Limitation of Liability. No provision hereof, in the absence of
affirmative action by the Holder to purchase shares of Common Stock, and no
enumeration herein of the rights or privileges of the Holder hereof, shall give
rise to any liability of the Holder for the purchase price of any Common Stock,
whether such liability is asserted by the Company or by creditors of the
Company.

      12. Miscellaneous.

      12.1. Nonwaiver and Expenses. No course of dealing or any delay or failure
to exercise any right hereunder on the part of the Holder shall operate as a
waiver of such right or otherwise prejudice the Holder's rights, powers or
remedies. If the Company fails to make, when due, any payments provided for
hereunder, or fails to comply with any other material provision of this Warrant,
the Company shall pay to the Holder such amounts as shall be sufficient to cover
any third party costs and expenses including, but not limited to, reasonable
attorneys' fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

      12.2. Notice Generally. Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (a) the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified on the signature pages attached hereto

                                       12
<PAGE>

prior to 5:00 p.m. (New York City time) on a Trading Day, (b) the next Trading
Day after the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number included with the address for the
recipient as provided herein on a day that is not a Trading Day or later than
5:00 p.m. (New York City time) on any Trading Day, (c) the Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as
follows:

      If to the Purchasers, at each Purchaser's address set forth in the books
and records of the Company, or with respect to the Company, addressed to:

                     Spectrum Pharmaceuticals, Inc.
                     157 Technology Drive
                     Irvine, California 92618
                     Attention: CEO
                     Facsimile No.: (949) 788-6706

or to such other address or addresses or facsimile number or numbers as any such
party may most recently have designated in writing to the other parties hereto
by such notice. Copies of notices to the Company shall be sent to:

                     Latham & Watkins LLP
                     650 Town Center Drive, Suite 2000
                     Costa Mesa, California 92626
                     Attention:  Alan W. Pettis
                     Facsimile No.: (714) 755-8290

      12.3. Successors and Assigns. Subject to compliance with the provisions of
Section 3.1, this Warrant and the rights evidenced hereby shall inure to the
benefit of and be binding upon the successors of the Company and the successors
and assigns of the Holder. The provisions of this Warrant are intended to be for
the benefit of all Holders from time to time of this Warrant, and shall be
enforceable by any such Holder.

      12.4. Amendment. This Warrant may be modified or amended or the provisions
of this Warrant waived with the written consent of both the Company and the
Holder.

      12.5. Severability. Wherever possible, each provision of this Warrant
shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Warrant shall be prohibited by or
invalid under applicable law, such provision shall be modified to the extent of
such prohibition or invalidity, without invalidating the remainder of such
provision or the remaining provisions of this Warrant.

      12.6. Headings. The headings used in this Warrant are for the convenience
of reference only and shall not, for any purpose, be deemed a part of this
Warrant.

      12.7. Governing Law. This Warrant and the transactions contemplated hereby
shall be deemed to be consummated in the State of New York and shall be governed
by and interpreted in

                                       13
<PAGE>

accordance with the local laws of the State of New York without regard to the
provisions thereof relating to conflicts of laws. The Company hereby irrevocably
consents to the exclusive jurisdiction of the State and Federal courts located
in New York City, New York in connection with any action or proceeding arising
out of or relating to this Warrant. In any such litigation the Company agrees
that the service thereof may be made by certified or registered mail directed to
the Company pursuant to Section 12.2.

                            [Signature Page Follows]

                                       14
<PAGE>

      IN WITNESS WHEREOF, Spectrum Pharmaceuticals, Inc. has caused this Warrant
to be executed by its duly authorized officer and attested by its Secretary.

Dated: September 30, 2004

                                              SPECTRUM PHARMACEUTICALS, INC.

                                              By:    /s/ Rajesh C. Shrotriya
                                                     ---------------------------
                                              Name:  Rajesh C. Shrotriya, M.D.
                                                     ---------------------------
                                              Title: Chairman, CEO and President
                                                     ---------------------------
Attest:

By:    /s/ Shyam Kumaria
      ---------------------------
Name:  Shyam Kumaria
      ---------------------------
Title: Secretary
      ---------------------------

                                       15
<PAGE>

                                    EXHIBIT A

                                SUBSCRIPTION FORM

                 [To be executed only upon exercise of Warrant]

      1. The undersigned registered owner of this Warrant hereby elects to
exercise this Warrant to purchase _______ shares of the Common Stock of Spectrum
Pharmaceuticals, Inc. pursuant to the terms of the attached Warrant, and tenders
herewith payment of the purchase price of such shares in full.

      2. By signing below, the undersigned hereby certifies that the exercise of
the Warrant for the number of shares of Common Stock indicated above will not
violate the limitation on the number of shares that may be acquired upon
exercise of the Warrant set forth in Section 2.3 of the Warrant.

      3. Please issue a certificate or certificates representing said shares of
Common Stock in the name of the undersigned or in such other name as is
specified below:
                                            ____________________________________
                                                         (Name)

                                            ____________________________________
                                            ____________________________________
                                            ____________________________________
                                                        (Address)

      [and, if such shares of Common Stock shall not include all of the shares
of Common Stock issuable as provided in this Warrant, that a new Warrant of like
tenor and date for the balance of the shares of Common Stock issuable hereunder
be delivered to the undersigned.]

_____________________________________
(Name of Registered Owner)

_____________________________________
(Signature of Registered Owner)

_____________________________________
(Street Address)

_____________________________________
(State) (Zip Code)

NOTICE: The signature on this subscription must correspond with the name as
written upon the face of the Warrant in every particular, without alteration or
enlargement or any change whatsoever.

                                       16
<PAGE>

                                    EXHIBIT B

                                 ASSIGNMENT FORM

FOR VALUE RECEIVED the undersigned registered owner of this Warrant for the
purchase of shares of common stock of Spectrum Pharmaceuticals, Inc. hereby
sells, assigns and transfers unto the Assignee named below all of the rights of
the undersigned under this Warrant, with respect to the number of shares of
common stock set forth below:

_____________________________________

_____________________________________

_____________________________________
(Name and Address of Assignee)

_____________________________________
(Number of Shares of Common Stock)

and does hereby irrevocably constitute and appoint ____________ attorney-in-fact
to register such transfer on the books of the Company, maintained for the
purpose, with full power of substitution in the premises.

Dated:_______________________________

_____________________________________
(Print Name and Title)

_____________________________________
(Signature)

_____________________________________
(Witness)

NOTICE: The signature on this assignment must correspond with the name as
written upon the face of the Warrant in every particular, without alteration or
enlargement or any change whatsoever.

                                       17
<PAGE>

                                    EXHIBIT C

                    FORM OF INVESTMENT REPRESENTATION LETTER

In connection with the acquisition of [warrants (the "Warrants") to purchase
____ shares of common stock of Spectrum Pharmaceuticals, Inc. (the "Company"),
par value $0.001 per share (the "Common Stock")][___shares of common stock of
Spectrum Pharmaceuticals, Inc. (the "Company"), par value $0.001 per share (the
"Common Stock") upon the exercise of warrants by ________], by _______________
(the "Holder") from _____________, the Holder hereby represents and warrants to
the Company as follows:

The Holder (i) is an "Accredited Investor" as that term is defined in Rule 501
of Regulation D promulgated under the Securities Act of 1933, as amended (the
"Act"); (ii) has the ability to bear the economic risks of such Holder's
prospective investment, including a complete loss of Holder's investment in the
Warrants and the shares of Common Stock issuable upon the exercise thereof
(collectively, the "Securities"); and (iii) is acquiring the securities such
Holder's own account for investment and not with a view to, or for sale in
connection with, any distribution thereof, nor with the intention of
distributing or reselling the same, provided, however, that by making the
representation herein, the Holder does not agree to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the
Securities at any time in accordance with or pursuant to a registration
statement or an exemption from registration under the Securities Act.

[The Holder acknowledges that (i) the Securities have not been registered under
the Act, (ii) the Securities are "restricted securities" and the certificate(s)
representing the Securities shall bear the following legend, or a similar legend
to the same effect, until (i) in the case of the shares of Common Stock
underlying the Warrants, such shares shall have been registered for resale by
the Holder under the Act and effectively been disposed of in accordance with a
registration statement that has been declared effective; (ii) such Securities
have been sold pursuant to and in accordance with Rule 144 under the Act; or
(iii) such Securities may be sold pursuant to and in accordance with Rule 144(k)
under the Act:

"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT UNLESS, IN THE OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH REGISTRATION IS NOT
REQUIRED."

                                       18
<PAGE>

IN WITNESS WHEREOF, the Holder has caused this Investment Representation Letter
to be executed this __ day of __________ 200_.

[Name]

By:______________________________
Name:
Title:
                                       19
<PAGE>
                                                                     Exhibit 4.1

                                   SCHEDULE I

<TABLE>
<CAPTION>
    WARRANT NUMBER               ENTITY NAME                 WARRANTS STOCK
    --------------               -----------                 --------------
<S>                       <C>                               <C>
       SPPI 267           SCO Capital Partners, LLC              63,970

       SPPI 272               Jeffrey B. Davis                   20,000

       SPPI 273                Daniel DiPietro                   7,650

       SPPI 274                 Preston Tsao                     6,380

       SPPI 275                  Mark Alvino                     2,000
</TABLE><PAGE>

                                                                    EXHIBIT 10.1

Confidential treatment has been requested for portions of this Exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [Intentionally Redacted]. A complete version of this
exhibit has been filed separately with the Securities and Exchange Commission.

                               CO-DEVELOPMENT AND

                                LICENSE AGREEMENT

                                     between

                              NEOTHERAPEUTICS, INC.

                                       and

                                 GPC BIOTECH AG

                         Dated as of September 30, 2002

<PAGE>

                               CO-DEVELOPMENT AND
                                LICENSE AGREEMENT

      This CO-DEVELOPMENT AND LICENSE AGREEMENT (this "Agreement"), dated as of
September 30, 2002, is between Neotherapeutics, Inc., a company duly organized
and existing under the laws of Delaware and having offices at 157 Technology
Drive, Irvine, California, USA for and on behalf of itself and its Affiliates
("NEOTHERAPEUTICS"), and GPC Biotech AG, a company duly organized and existing
under the laws of the Federal Republic of Germany and having offices at
Fraunhoferstrasse 20, D-82152 Martinsried/Munich Germany, for and on behalf of
itself and its Affiliates (together with its Affiliates, "GPC").

                             PRELIMINARY STATEMENTS

      A.    NEOTHERAPEUTICS has entered into that certain License Agreement with
Johnson Matthey PLC ("J-M") dated August 28, 2001, pursuant to which
NEOTHERAPEUTICS has been granted a license, with the right to sublicense, to
certain patent rights and other know-how and technology owned by J-M.

      B.    NEOTHERAPEUTICS wishes to grant a sublicense to GPC, and GPC wishes
to take a sublicense from NEOTHERAPEUTICS, under certain rights granted to
NEOTHERAPEUTICS under the J-M License Agreement and under other relevant patent
rights and know-how controlled by NEOTHERAPEUTICS, upon the terms and conditions
set forth in this Agreement.

      NOW, THEREFORE, in consideration of the foregoing preliminary statements
and the mutual covenants and agreements of the Parties contained in this
Agreement, the Parties hereby agree as follows:

1.    DEFINITIONS

      As used in this Agreement, the following terms shall have those meanings
set forth in this Section 1 unless the context dictates otherwise.

      1.1.  "Affiliate" with respect to either Party, shall mean any Person
controlling, controlled by, or under common control with, such Party. For the
purpose of this Section 1.1, "control" shall refer to (i) the possession,
directly or indirectly, of the power to direct the management or policies of
such Party, whether through the ownership of voting securities, by contract or
otherwise, or (ii) the beneficial ownership (as such term is defined in the 1934
Act) of at least fifty percent (50%) of the voting securities or other ownership
interest of such Party.

      1.2.  "Confidential Information" shall have the meaning assigned to such
term in Section 12.1.

      1.3.  "Covered Product" shall mean any Platinum Complexes formulated for
administration to humans, the research, development, manufacture, sale or use of
which in any country in the Territory is covered by a Valid Claim of any Patent
included in the J-M Licensed Technology or the NEOTHERAPEUTICS Licensed
Technology.

<PAGE>

      1.4.  "Effective Date" shall mean the date first set forth above.

      1.5.  "EMEA" shall mean the European Agency for the Evaluation of
Medicinal Products and any successor thereto.

      1.6.  "FDA" shall mean the United States Food and Drug Administration, or
any successor thereto.

      1.7.  "Field" shall mean the FIELD, as such term is defined in the J-M
License Agreement, as amended from time to time.

      1.8.  "First Commercial Sale" shall mean, with respect to any Covered
Product, the first sale for use or consumption by the general public of such
Covered Product in a country in the Territory after all required marketing and
pricing approvals have been granted, or otherwise permitted, by the governing
health authority of such country. "First Commercial Sale" shall not include the
sale of any Covered Product for use in clinical trials or for compassionate use
prior to the approval of an NDA.

      1.9.  "GPC Development Technology" shall mean all Inventions and Know-How
first developed, reduced to practice or shown to have utility by one or more
employees of GPC without the involvement of one or more employees of
NEOTHERAPEUTICS in connection with the development of Covered Products, as well
as any and all Patents covering the same.

      1.10. "Invention" shall mean any new or useful method, process,
manufacture, compound or composition of matter, whether or not patentable or
copyrightable, or any improvement thereof.

      1.11. "J-M License Agreement" shall mean that certain License Agreement
dated August 28, 2001, by and between NEOTHERAPEUTICS and J-M, as amended from
time to time. A copy of such Agreement, including all amendments executed prior
to the execution of this Agreement, is attached hereto as Exhibit A.

      1.12. "J-M Licensed Technology" shall mean the J-M Patent Rights, the
LICENSOR'S INFORMATION and the LICENSOR'S ONGOING INFORMATION to which
NEOTHERAPEUTICS has been granted a license under the J-M License Agreement, as
such capitalized terms are defined in the J-M License Agreement, as amended from
time to time.

      1.13. "J-M Patent Rights" shall mean the PATENT RIGHTS, as such term is
defined in the J-M Licensed Agreement. A list of all such J-M Patent Rights in
existence on the Effective Date is included in Exhibit B attached hereto.

      1.14. "J-M Royalty Term" shall mean the period beginning on the Effective
Date and ending on the earlier of (i) the expiration of the TERM, as such term
is defined

<PAGE>

in the J-M License Agreement, as amended from time to time, or (ii) the date on
which NEOTHERAPEUTICS is no longer required to make royalty payments to J-M
pursuant to the J-M License Agreement.

      1.15. "Joint Development Committee" shall mean the entity organized and
acting pursuant to Section 4.

      1.16. "Joint Development Technology" shall mean all Inventions and
Know-How first developed, reduced to practice or shown to have utility by one or
more employees of GPC and one or more employees of NEOTHERAPEUTICS in connection
with the development of Covered Products, as well as any and all Patents
covering the same.

      1.17. "Know-How" shall mean unpatented technical and other information
which is not in the public domain including information comprising or relating
to discoveries, inventions, data, designs, formulae, methods, models, assays,
research plans, procedures, designs for experiments and tests and results of
experimentation and testing (including results of research or development),
processes (including manufacturing processes, specifications and techniques),
laboratory records, chemical, pharmacological, toxicological, clinical,
analytical and quality control data, trial data, case report forms, data
analyses, reports or summaries and information contained in submissions to and
information from ethical committees and regulatory authorities. Know-How
includes rights protecting Know-How. The fact that an item is known to the
public shall not be taken to exclude the possibility that a compilation
including the item, and/or a development relating to the item, is (and remains)
not known to the public.

      1.18. "MAA" shall mean a Marketing Authorization Application or similar
application filed with the EMEA after completion of human clinical trials to
obtain marketing approval for a Covered Product in the European Union.

      1.19. "MHW" shall mean the Ministry of Health and Welfare in Japan and any
successor agency.

      1.20. "NDA" shall mean a New Drug Application to be filed with the FDA, or
the equivalent thereof in other countries or regulatory jurisdictions.

      1.21. "NEOTHERAPEUTICS Development Technology" shall mean all Inventions
and Know-How first developed, reduced to practice or shown to have utility by
one or more employees of NEOTHERAPEUTICS without the involvement of one or more
employees of GPC in connection with the development of Covered Products, as well
as any and all Patents covering the same.

      1.22. "NEOTHERAPEUTICS Licensed Technology" shall mean the LICENSEE'S
ONGOING INFORMATION, as such term is defined in the J-M License Agreement, as
amended from time to time, as well as all Patents owned or controlled by, or
licensed to, NEOTHERAPEUTICS, and all Know-How and Inventions developed, owned
or controlled by, or licensed to, NEOTHERAPEUTICS, on or after the Effective
Date, other than the J-M Licensed Technology, which, by objective standards, is

<PAGE>

necessary for or may be useful in the development, manufacture, use or sale of
Licensed Products in the Field in the Territory, all to the extent that
NEOTHERAPEUTICS has the right to license or otherwise make available such
Patents, Know-How and Inventions to GPC hereunder. A list of all such Patents in
existence on the Effective Date is included in Exhibit B attached hereto.

      1.23. "Net Sales" shall have the meaning ascribed to the term "Net Sales
Value" in the J-M License Agreement, as amended from time to time.

      Notwithstanding the foregoing, in the event a Covered Product is sold in
conjunction with another proprietary component so as to be a combination product
(whether packaged together or in the same therapeutic formulation), Net Sales
shall be calculated by multiplying the Net Sales of such combination product by
a fraction, the numerator of which shall be the fair market value of the Covered
Product as if sold separately (determined in accordance with generally accepted
accounting principles), and the denominator of which shall be the aggregate fair
market value of all the proprietary active components of such combination
product, including the Covered Product, as if sold separately. In the event no
such separate sales are made by GPC or its Affiliates, Net Sales of the
combination product shall be calculated in a manner to be negotiated and agreed
upon by the Parties, reasonably and in good faith, prior to any sale of such
combination product, which shall be based upon the respective estimated
commercial values of the proprietary active components of such combination
product.

      GPC's or any of its Affiliate's transfer of Covered Product to another
Affiliate or a Sublicensee shall not result in any Net Sales, unless such
Covered Product is consumed by such Affiliate or Sublicensee in the course of
its commercial activities.

      1.24. "1934 Act" shall mean the U.S. Securities Exchange Act of 1934, as
amended, and all regulations promulgated pursuant thereto from time to time.

      1.25. "Party" shall mean NEOTHERAPEUTICS or GPC and, when used in the
plural, shall mean NEOTHERAPEUTICS and GPC.

      1.26. "Patents" shall mean all letters patent and patent applications
throughout the Territory, as well as any and all substitutions, extensions,
renewals, continuations, continuations-in-part, divisions, patents-of-addition
and/or reissues thereof.

      1.27. "Person" shall mean any natural person, corporation, firm, business
trust, joint venture, association, organization, company, partnership or other
business entity, or any government or any agency or political subdivision
thereof.

      1.28. "Platinum Complexes" shall mean the platinum co-ordination compounds
that are the subject of the J-M Patent Rights.

      1.29. "Royalty Term" shall mean the period beginning on the Effective Date
and ending on the date of the expiration of the last to expire Valid Claim, if
any, included in the Joint Development Technology or NEOTHERAPEUTICS Development
Technology

<PAGE>

that covers the manufacture or sale of Covered Products. If, at the time of
expiration of the J-M Royalty Term, there are no Valid Claims included in the
Joint Development Technology or NEOTHERAPEUTICS Development Technology covering
the manufacture or sale of a Covered Product, then the Royalty Term with respect
to such Covered Product shall expire on the expiration of the J-M Royalty Term.

      1.30. "Satraplatin" shall mean the platinum complex
bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).

      1.31. "Sublicensee" shall mean a Third Party to which GPC has sublicensed
rights under the NEOTHERAPEUTICS Licensed Technology or J-M Licensed Technology
for the commercialization of Covered Products.

      1.32. "Sublicense Fees" shall mean all payments made to GPC from a
Sublicensee that relate specifically to the sublicense of rights granted to GPC
hereunder, excluding (i) payments made in consideration of research and
development efforts undertaken by GPC, (ii) payments made to reimburse GPC for
expenses previously incurred by GPC in connection with the development of
Covered Products, (iii) payments made in consideration of the purchase of equity
of GPC by a Sublicensee to the extent that such payments do not exceed the fair
market value of such equity, (iv) payments made in consideration of the
manufacture or supply of Covered Products by GPC to the extent that such
payments do not exceed GPC's costs of such manufacture and supply, (v) loans
made to GPC or (vi) Sublicense Royalties.

      1.33. "Sublicense Royalties" shall mean royalty payments made to GPC based
on sales of Covered Products by a Sublicensee.

      1.34. "Territory" shall mean the entire world.

      1.35. "Third Party" shall mean any Person who or which is neither a Party
nor an Affiliate of a Party.

      1.36. "Valid Claim" shall mean (i) a pending claim in any patent
application that has not been pending for more than five (5) years, which shall
be treated as if such pending claim were issued in then-current form, or (ii) a
claim of any issued letters patent that, in each case, has not been held invalid
or unenforceable by final decision of a court or other governmental agency of
competent jurisdiction, unappealable or unappealed within the time allowed for
appeal, and that is not admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise.

2.    REPRESENTATIONS AND WARRANTIES

      2.1.  REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES. Each Party
represents and warrants to the other Party that, as of the Effective Date:

      (a)   Such Party is duly organized and validly existing under the laws of
the jurisdiction of its incorporation and has full corporate power and authority
to enter into this Agreement and to carry out the provisions hereof;

<PAGE>

      (b)   Such Party has taken all corporate action necessary to authorize the
execution and delivery of this Agreement and the performance of its obligations
under this Agreement; and

      (c)   This Agreement is a legal and valid obligation of such Party,
binding upon such Party and enforceable against such Party in accordance with
the terms of this Agreement, except as such enforceability may be affected by
laws affecting creditors' rights generally and general equitable principles. The
execution, delivery and performance of this Agreement by such Party do not
conflict with any agreement, instrument or understanding, oral or written, to
which such Party is a party or by which such Party may be bound, or violate any
law or regulation of any court, governmental body or administrative or other
agency having authority over such Party. All consents, approvals and
authorizations from all governmental authorities or other Third Parties required
to be obtained by such Party in connection with the execution, delivery and
performance of this Agreement have been obtained.

      2.2.  ADDITIONAL REPRESENTATIONS AND WARRANTIES OF NEOTHERAPEUTICS.
NEOTHERAPEUTICS represents and warrants to GPC that, as of the Effective Date:

      (a)   NEOTHERAPEUTICS and/or its Affiliates are the owner of, or have
exclusive rights to, all of the Patents included in the J-M Licensed Technology
(except as expressly provided in the copy of the J-M License Agreement attached
as Exhibit A) and the NEOTHERAPEUTICS Licensed Technology in existence on the
Effective Date, and have the exclusive right to grant the licenses or
sublicenses, as the case may be, therefor granted under this Agreement;

      (b)   All such Patents consist of either patent applications that have
been filed and are pending and actively being prosecuted as of the Effective
Date, or issued letters patent that are in full force and effect and have been
maintained through the Effective Date;

      (c)   NEOTHERAPEUTICS is not aware of any asserted or unasserted claim or
demand which it believes can be enforced by a Third Party against any such
Patents;

      (d)   To the best of NEOTHERAPEUTICS's knowledge and belief, the practice
of such Patents and the exercise of the rights granted to GPC in Section 7 do
not infringe upon or conflict with any patent, copyright or other proprietary
right of any Third Party;

      (e)   NEOTHERAPEUTICS and/or its Affiliates have the right to grant the
licenses or sublicenses, as the case may be, granted under this Agreement for
all of the Know-How and Inventions included in the J-M Licensed Technology and
NEOTHERAPEUTICS Licensed Technology in existence on the Effective Date;

      (f)   Such Know-How and Inventions were not obtained by NEOTHERAPEUTICS,
and to the best of NEOTHERAPEUTICS's knowledge and belief were not obtained by
J-M, in violation of any contractual or fiduciary obligation to which
NEOTHERAPEUTICS, J-M or any of their respective employees or staff members are
or were bound, or by the misappropriation of the trade secrets of any Third
Party;

<PAGE>

      (g)   NEOTHERAPEUTICS has not entered into any agreement with any Third
Party which is in conflict with the rights granted to GPC under to this
Agreement, and the execution and performance of this Agreement by
NEOTHERAPEUTICS do not and shall not violate any agreement or undertaking to
which NEOTHERAPEUTICS is a party; and

      (h)   To the best of NEOTHERAPEUTICS's knowledge and belief, all of the
data and information that NEOTHERAPEUTICS has provided to GPC prior to the
Effective Date relating to such Patents, Know-How and Inventions, and to Covered
Products in general, are reasonably accurate, and NEOTHERAPEUTICS has not
omitted therefrom any material data or information in NEOTHERAPEUTICS's
possession or control reasonably in advance of the Effective Date concerning the
same.

      2.3.  REPRESENTATIONS AND WARRANTIES OF GPC. GPC represents and warrants
to NEOTHERAPEUTICS that, as of the Effective Date:

      (a)   Experience. GPC acknowledges that it can bear the economic risk of
its investment in the NEOTHERAPEUTICS Shares. GPC has by reason of its business
or financial experience or the business or financial experience of its
professional advisors who are unaffiliated with and who are not compensated by
NEOTHERAPEUTICS or any affiliate or selling agent of NEOTHERAPEUTICS, directly
or indirectly, has the capacity to protect its own interests in connection with
its purchase of the NEOTHERAPEUTICS Shares. GPC has the financial capacity to
bear the risk of this investment.

      (c)   Purchase Entirely for Own Account. The NEOTHERAPEUTICS Shares will
be acquired by GPC for investment for GPC's own account not as a nominee or
agent, and not with a view to the resale or distribution of any part thereof,
and GPC has no present intention of selling, granting any participation in, or
otherwise distributing the same. GPC does not presently have any contract,
undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the
NEOTHERAPEUTICS Shares. GPC has not been formed for the specific purpose of
acquiring solely the NEOTHERAPEUTICS Shares.

      (e)   Disclosure of Information. GPC has received and reviewed information
about NEOTHERAPEUTICS, and in particular about the Patents, Know-How, Inventions
and Covered Products, and has had an opportunity to discuss NEOTHERAPEUTICS's
business, management and financial affairs with its management and to review
NEOTHERAPEUTICS's facilities. GPC understands and acknowledges that such
discussions, as well as any written information issued by NEOTHERAPEUTICS (i)
were intended to describe the aspects of NEOTHERAPEUTICS's business and
prospects which NEOTHERAPEUTICS believes to be material, but were not
necessarily an exhaustive description (except to the extent described in Section
2.2(h)), and (ii) may have contained forward-looking statements involving known
and unknown risks and uncertainties which may cause NEOTHERAPEUTICS's actual
results in future periods

<PAGE>

or plans for future periods to differ materially from what was anticipated and
that no representations or warranties were or are being made with respect to any
such forward-looking statements or the probability of achieving any of the
results projected in any of such forward-looking statements. Nothing contained
in this Section 2.3 shall limit in any respect NEOTHERAPEUTICS's representations
and warranties contained in this Agreement.

      (g)   Restricted Securities. GPC understands that the NEOTHERAPEUTICS
Shares have not been, and will not, prior to issuance under Section 9.1(c), be,
registered under the Securities Act of 1933, as amended (the "Securities Act"),
by reason of a specific exemption from the registration provisions of the
Securities Act which depends upon, among other things, the bona fide nature of
the investment intent and the accuracy of GPC's representations as expressed
herein. GPC understands that the NEOTHERAPEUTICS Shares are "restricted
securities" under applicable U.S. federal and state securities laws and that,
pursuant to these laws, GPC must hold the NEOTHERAPEUTICS Shares indefinitely
unless they are registered with the SEC and qualified by state authorities, or
an exemption from such registration and qualification requirements is available.
GPC acknowledges that NEOTHERAPEUTICS has no obligation to register or qualify
the NEOTHERAPEUTICS Shares for resale except as set forth in the Registration
Rights Agreement to be entered into as provided in Section 9.1(c). GPC further
acknowledges that if an exemption from registration or qualification is
available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the
NEOTHERAPEUTICS Shares, and on requirements relating to NEOTHERAPEUTICS which
are outside of GPC's control, and which NEOTHERAPEUTICS is under no obligation
and may not be able to satisfy. GPC acknowledges that NEOTHERAPEUTICS will make
a notation on its stock books regarding the restrictions on transfers set forth
in this Section 2.3 and will transfer securities on the books of NEOTHERAPEUTICS
only to the extent not inconsistent therewith.

      (i)   Residence. The office or offices of GPC in which its investment
decision was made is located at the address or addresses of GPC set forth in the
preamble.

      (k)   Further Restrictions on Disposition. GPC agrees not to make any
disposition of all or any portion of the NEOTHERAPEUTICS Shares unless and
until: (a) there is then in effect a registration statement under the Securities
Act covering such proposed disposition and the disposition is made in accordance
with such registration statement; or (b) (i) GPC shall have notified
NEOTHERAPEUTICS of the proposed disposition and shall have furnished
NEOTHERAPEUTICS with a statement of the circumstances surrounding the proposed
disposition and (ii) if reasonably requested by NEOTHERAPEUTICS, GPC shall have
furnished NEOTHERAPEUTICS with an opinion of counsel, reasonably acceptable to
NEOTHERAPEUTICS, that such disposition will not require registration under the
Securities Act.

      (m)   Legends. GPC understands that the NEOTHERAPEUTICS Shares, and
any securities issued in respect of or exchange for the NEOTHERAPEUTICS Shares,
may bear one or all of the following legends until they are no longer required
by law or the provisions of this Agreement:

<PAGE>

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, (THE "SECURITIES ACT") PURSUANT TO AN
EXEMPTION FROM REGISTRATION CONTAINED IN REGULATION S PROMULGATED UNDER THE
SECURITIES ACT, AND MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE
PROVISIONS OF REGULATION S, PURSUANT TO A REGISTRATION UNDER THE SECURITIES ACT
OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. NO HEDGING TRANSACTIONS
INVOLVING THESE SECURITIES MAY BE CONDUCTED EXCEPT IN COMPLIANCE WITH THE
SECURITIES ACT."

Any legend required by the Blue Sky laws of any state to the extent such laws
are applicable to the shares represented by the certificate so legended.

The legend set forth above shall be removed by NEOTHERAPEUTICS from any
certificate evidencing NEOTHERAPEUTICS Shares upon transfer of such
NEOTHERAPEUTICS Shares in compliance with Rule 144(k) under the Securities Act
or upon delivery to NEOTHERAPEUTICS of an opinion, in form and substance and by
counsel reasonably satisfactory to NEOTHERAPEUTICS, that a registration
statement under the Securities Act is at that time in effect with respect to the
legended security or that such security can be freely transferred without such a
registration statement being in effect and that such transfer will not
jeopardize the exemption or exemptions from registration pursuant to which the
securities were issued.

      (o)   Foreign Investors. GPC hereby represents that it has satisfied
itself as to the full observance of the laws of its jurisdiction in connection
with any invitation to subscribe for the NEOTHERAPEUTICS Shares or any use of
this Agreement, including (i) the legal requirements within its jurisdiction for
the purchase of the NEOTHERAPEUTICS Shares, (ii) any foreign exchange
restrictions applicable to such purchase, (iii) any governmental or other
consents that may need to be obtained, and (iv) the income tax and other tax
consequences, if any, that may be relevant to the purchase, holding, redemption,
sale, or transfer of the NEOTHERAPEUTICS Shares. GPC's subscription and payment
for and continued beneficial ownership of the NEOTHERAPEUTICS Shares, will not
violate any applicable securities or other laws of GPC's jurisdiction and will
not require NEOTHERAPEUTICS to obtain any permit, make any filing or take any
other action in such jurisdiction.

      (q)   Offshore Transaction.

            (i)   GPC is not organized under the laws of or is not a citizen or
      resident of the United States and was not formed for the purpose of
      investing in Regulation S securities, does not have any of its securities
      registered under the Exchange Act, and is not owned by U.S. Persons as
      defined in Regulation S and herein.

<PAGE>

            (ii)  At the time the buy order to purchase the NEOTHERAPEUTICS
      Shares was originated, GPC was outside the United States.

            (iii) All subsequent offers and sales of the NEOTHERAPEUTICS Shares
      shall be made in compliance with Regulation S, pursuant to registration of
      the securities under the Securities Act or pursuant to an exemption from
      such registration.

            (iv)  GPC agrees that from the date hereof until after one year
      after the issuance of the NEOTHERAPEUTICS Shares hereunder (the
      "Restrictive Period"), GPC agrees, upon any offer, sale, or transfer of
      the NEOTHERAPEUTICS Shares (including any interests therein), GPC, or any
      successor, or any Professional under its direction (as defined below)
      (except for sales of any NEOTHERAPEUTICS Shares registered under the
      Securities Act or otherwise exempt from such registration) (i) will not
      sell to a U.S. Person or to an account of or for the benefit of a U.S.
      Person or to anyone believed to be a U.S. Person; (ii) will not engage in
      any efforts to sell the NEOTHERAPEUTICS Shares in the United States; (iii)
      will, at the time the buy order or transfer is originated, believe the
      buyer or transferee is outside the United States; (iv) will send to any
      transferee who is a Professional, whether acting as agent or principal, a
      confirmation or other notice stating that the Professional is subject to
      the same restrictions on transfer to U.S. Persons or for the account of or
      benefit of U.S. Persons during the Restrictive Period as provided herein;
      and (v) will not in connection with the common stock of NEOTHERAPEUTICS
      engage in the United States in any short selling, option writing, equity
      swaps, or other types of hedging transactions or derivative transactions.
      NEOTHERAPEUTICS will not honor or register and will not be obligated to
      honor or register any transfer in violation of these provisions.

            (v)   For purpose hereof, in general, a "U.S. Person;" means any
      natural person, resident of the United States; any partnership or
      corporation organized or incorporated under the laws of the United States
      or any state or territory thereof; any estate of which any executor or
      administrator is a U.S. Person; any trust of which any trustee is a U.S.
      Person; any agency or branch of a foreign entity located in the United
      States; any nondiscretionary account or similar account, other than estate
      or trust, held by a dealer or other fiduciary organized, incorporated, or
      (if an individual) resident of the United States; and any partnership or
      corporation if organized or incorporated under the laws of any foreign
      jurisdiction and formed by a U.S. Person principally for the purpose of
      investing in securities and not registered under the Securities Act unless
      it is organized and incorporated and owned by "accredited investors," as
      defined under Rule 501(a) under the Securities Act, who are not natural
      persons, estates or trusts. "U.S. Person" is further defined in Rule
      902(o) under the Securities Act.

            (vi)  A "Professional" is a "distributor" as defined in Rule 902(c)
      under the Securities Act (generally any underwriter, or other person, who
      participates, pursuant to a contractual arrangement, in the distribution
      of the Shares); a dealer

<PAGE>

      as defined in Section 2(12) of the Exchange Act (encompassing those who
      engage in the business of trading or dealing in securities as agent,
      broker, or principal); or a person receiving a selling concession, fee, or
      other remuneration in respect of the sale of the Shares sold.

      2.4.  DEFINITION OF "KNOWLEGE." As used in this Section 2, the phrases "to
the best of" a Party's "knowledge and belief," "known to" or similar phrases are
intended to indicate that no information has come to the attention of senior
management of the Party making the particular representation which would give
such person actual knowledge of the existence or absence of such facts.

3.    J-M LICENSE AGREEMENT

      3.1.  REPRESENTATIONS AND WARRANTIES OF NEOTHERAPEUTICS. NEOTHERAPEUTICS
represents and warrants to GPC that, as of the Effective Date:

      (a)   The J-M License Agreement is in full force and effect and has not
been modified or amended, except that no representation or warranty is made with
respect to J-M or matters solely within the control or direction of J-M that are
not known to NEOTHERAPEUTICS;

      (b)   To the best of NEOTHERAPEUTICS's knowledge and belief, neither J-M
nor NEOTHERAPEUTICS is in default with respect to a material obligation under,
and neither such party has claimed or has grounds upon which to claim that the
other party is in default with respect to a material obligation under, the J-M
License Agreement;

      (c)   To the best of NEOTHERAPEUTICS's knowledge and belief, the rights
that J-M has licensed to NEOTHERAPEUTICS pursuant to the J-M License Agreement
were not and are not subject to any restrictions or limitations except as set
forth in the copy of the J-M License Agreement attached as Exhibit A; and

      (d)   NEOTHERAPEUTICS has not waived or allowed to lapse any of its rights
under the J-M License Agreement, and no such rights have lapsed or otherwise
expired or been terminated.

      3.2.  NEOTHERAPEUTICS OBLIGATIONS. NEOTHERAPEUTICS agrees that during the
term of this Agreement:

      (a)   NEOTHERAPEUTICS will use commercially reasonable efforts to fulfill
its obligations under the J-M License Agreement to the extent such obligations
have not been delegated to GPC and to the extent that failure to do so would
adversely affect GPC or its rights hereunder;

      (b)   NEOTHERAPEUTICS shall not enter into any subsequent agreement with
J-M that modifies or amends the J-M License Agreement in any way that could
potentially adversely affect GPC's rights or economic interest under this
Agreement without GPC's prior written consent, and shall provide GPC with a copy
of all modifications to or amendments of the J-M License Agreement, regardless
of whether

<PAGE>

GPC's consent was required with respect thereto; provided that, NEOTHERAPEUTICS
may redact confidential portions of any such modifications and amendments, but
only to the extent that any such redactions do not impair GPC's ability to take
full advantage of its rights and benefits under this Agreement;

      (c)   NEOTHERAPEUTICS shall not terminate the J-M License Agreement in
whole or in part, directly or indirectly, without GPC's prior written consent;

      (d)   NEOTHERAPEUTICS shall promptly furnish GPC with copies of all
reports and other communications NEOTHERAPEUTICS receives from J-M that relate
to the subject matter of this Agreement;

      (e)   NEOTHERAPEUTICS shall promptly furnish GPC with copies of all
reports and other communications that NEOTHERAPEUTICS furnishes to J-M that
relate to the subject of this Agreement, and to the extent any such reports or
communications relate to the efforts of GPC under this Agreement,
NEOTHERAPEUTICS shall give GPC a reasonable opportunity to review and comment
upon such reports or communications before they are transmitted to J-M;

      (f)   NEOTHERAPEUTICS shall furnish GPC with copies of all notices
received by NEOTHERAPEUTICS relating to any alleged breach or default by
NEOTHERAPEUTICS under the J-M License Agreement within three (3) business days
after NEOTHERAPEUTICS's receipt thereof and, if NEOTHERAPEUTICS cannot or
chooses not to cure or otherwise resolve any such alleged breach or default,
NEOTHERAPEUTICS shall so notify GPC within five (5) days thereafter and allow
GPC, in GPC's sole discretion, to cure or otherwise resolve any such alleged
breach or default; and

      (g)   NEOTHERAPEUTICS, acting as an intermediary between J-M and GPC,
shall allow GPC to enjoy the direct benefit of all of NEOTHERAPEUTICS's
affirmative rights, to the extent they relate to the J-M Licensed Technology.

4.    JOINT DEVELOPMENT COMMITTEE

      4.1.  MEMBERS. The Parties shall establish a Joint Development Committee
(the "Joint Development Committee"), which shall comprise three (3)
representatives designated by each Party (or such other number as the Parties
may agree in writing). The initial members of the Joint Development Committee
are set forth on Exhibit C. Any Member of the Joint Development Committee may be
represented at any meeting by a designee who is appointed by such member for
such meeting and who has authority to act on behalf of such member, as evidenced
by written notice from such Member to the chairperson of the Joint Development
Committee. The chairperson of the Joint Development Committee shall be one of
the representatives designated by GPC. The initial chairperson is designated on
Exhibit C. Each Party shall be free to replace its representative members with
new appointees who have authority to act on behalf of such Party on the Joint
Development Committee, on written notice to the other Party.

<PAGE>

      4.2.  RESPONSIBILITIES. The Joint Development Committee shall be
responsible for planning, overseeing and directing the development and
commercialization of, and regulatory filings relating to, Covered Products.

      4.3.  MEETINGS. The Joint Development Committee shall meet quarterly until
the achievement of the first milestone described in Section 9.2 and, thereafter,
as frequently as the Parties deem appropriate, on such dates and at such times
as the Parties shall agree, on ten (10) days' written notice to the other Party
unless such notice is waived by the other Party. The Joint Development Committee
may convene or be polled or consulted from time to time by means of
telecommunications, video conferences or correspondence, as deemed necessary or
appropriate by the Parties. To the extent that meetings are held in person, they
shall alternate between the offices of the Parties unless the Parties otherwise
agree. The chairperson shall be responsible for sending notices of meetings to
all members.

      4.4.  DECISIONS.

      (a)   A quorum for a meeting of the Joint Development Committee shall
require the presence of at least one NEOTHERAPEUTICS member (or designee) and at
least one GPC member (or designee) in person or by telephone. All decisions made
or actions taken by the Joint Development Committee shall be made unanimously by
its members, with the NEOTHERAPEUTICS members cumulatively having one vote and
the GPC members cumulatively having one vote.

      (b)   In the event that unanimity cannot be reached by the Joint
Development Committee with respect to a matter that is a subject of its
decision-making authority within thirty (30) days after the matter is first
brought before the Joint Development Committee, then the matter shall be decided
by the chairperson of the Joint Development Committee in good faith.

      4.5.  MINUTES. Within fifteen (15) days after each Joint Development
Committee meeting, GPC shall prepare and distribute minutes of the meeting,
which shall provide a description in reasonable detail of the discussions had at
the meeting and a list of any actions, decisions or determinations approved by
the Joint Development Committee at such meeting. GPC shall be responsible for
circulation of all draft and final minutes. Draft minutes shall be circulated to
all members of the Joint Development Committee sufficiently in advance of the
next meeting to allow review and comment prior to the meeting. Minutes shall be
approved or disapproved, and revised as necessary, at the next meeting. Final
minutes shall be distributed to the members of the Joint Development Committee.

      4.6.  TERM. The Joint Development Committee shall exist until the
expiration of the Royalty Term for all Covered Products.

      4.7.  EXPENSES. Each Party shall be responsible for all travel and related
costs for its representatives to attend meetings of, and otherwise participate
on, the Joint Development Committee.

<PAGE>

      4.8.  ADDITIONAL STUDIES. NEOTHERAPEUTICS reserves the right, subject to
the approval and oversight of the Joint Development Committee, which approval
will not be unreasonably withheld, to propose additional studies of Satraplatin
at its own expense.

      5.    CO-PROMOTION. In the event GPC determines to directly market Covered
Products in the United States itself rather than licensing such Covered Products
to a Third Party for commercialization, GPC shall notify NEOTHERAPEUTICS in
writing reasonably in advance of the commencement of commercialization of any
such Covered Product. If, within ten (10) days after receipt of such notice from
GPC, NEOTHERAPEUTICS indicates in writing to GPC that it desires to co-promote
such Covered Product with GPC, the Parties shall negotiate in good faith the
terms of such co-promotion of such Covered Product. If GPC proposes to enter
into an agreement with a Third Party that includes a grant of rights to such
Third Party to market a Covered Product in the United States, GPC shall use
commercially reasonable efforts to obtain co-promotion rights in the United
States with such Third Party that include NEOTHERAPEUTICS.

6.    OWNERSHIP; PATENT PROTECTION

      6.1.  OWNERSHIP OF GPC DEVELOPMENT TECHNOLOGY. Except as otherwise
provided in this Agreement, the entire right, title and interest in and to all
GPC Development Technology shall be owned solely by GPC, and all decisions
regarding the protection of GPC Development Technology shall remain with GPC.

      6.2.  OWNERSHIP OF J-M LICENSED TECHNOLOGY, NEOTHERAPEUTICS LICENSED
TECHNOLOGY, NEOTHERAPEUTICS DEVELOPMENT TECHNOLOGY. Except as otherwise provided
in this Agreement, the entire right, title and interest in and to all
NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS Development Technology
and, as between the Parties, J-M Licensed Technology shall be owned solely by
NEOTHERAPEUTICS, and, except as otherwise set forth in this Agreement or the J-M
License Agreement, all decisions regarding the protection of J-M Licensed
Technology, NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS Development
Technology shall remain with NEOTHERAPEUTICS.

      6.3.  OWNERSHIP OF JOINT DEVELOPMENT TECHNOLOGY. GPC and NEOTHERAPEUTICS
shall jointly own all rights, title and interests in Joint Development
Technology.

      6.4.  PATENT FILING, PROSECUTION AND MAINTENANCE.

      (a)   Reasonably promptly after the Effective Date the Joint Development
Committee, in consultation with the Parties' respective patent counsel, shall
agree upon a patent filing policy with respect to the NEOTHERAPEUTICS Licensed
Technology, the Joint Development Technology and the NEOTHERAPEUTICS Development
Technology. In addition, from time to time, the Joint Development Committee
shall determine, in accordance with such policy, whether and in what
jurisdictions patent applications should be filed with respect to any Know-How
or Inventions included in the NEOTHERAPEUTICS Licensed Technology, the Joint
Development Technology and the NEOTHERAPEUTICS Development Technology.

<PAGE>

      (b)   Following a determination by the Joint Development Committee that a
patent application should be filed with respect to any Know-How or Inventions
included in the NEOTHERAPEUTICS Licensed Technology, NEOTHERAPEUTICS, through
outside patent counsel (including, without limitation, foreign patent counsel
and agents) reasonably acceptable to GPC, shall promptly file a patent
application with respect thereto in the jurisdiction(s) selected by the Joint
Development Committee, and thereafter NEOTHERAPEUTICS shall prosecute such
application and maintain any letters patent issuing therefrom. NEOTHERAPEUTICS
shall take all such actions in consultation with GPC and its patent counsel and
shall keep GPC apprised as to the status of all pending patent applications. The
out-of-pocket costs of filing, prosecuting and maintaining any Patents actually
incurred by NEOTHERAPEUTICS under this Section 6.3(b) shall be reimbursed by
GPC. NEOTHERAPEUTICS shall invoice GPC for such costs on a quarterly basis. Such
invoices shall be payable forty-five (45) days after receipt thereof. If the
Joint Development Committee determines to not have a patent application filed
with respect to any Know-How or Inventions included in the NEOTHERAPEUTICS
Licensed Technology, NEOTHERAPEUTICS may, notwithstanding anything else
contained herein, file, prosecute and maintain a patent application and any
letters patent issuing therefrom at its own expense.

      (c)   The preparation, filing, prosecuting and maintenance of Patents
included in the J-M Licensed Technology shall be accomplished as provided in the
J-M License Agreement, subject to the provisions of this Agreement. Furthermore,
the Parties' respective rights and obligations under this Section shall be
subject, in all events, to any superior rights of J-M under the J-M License
Agreement regarding the J-M Licensed Technology.

      (d)   If J-M elects to abandon the prosecution or maintenance of any J-M
Patent Right in any country pursuant to Section 1 of Article VII of the J-M
License Agreement and NEOTHERAPEUTICS elects not to assume the prosecution or
maintenance of such J-M Patent Right, NEOTHERAPEUTICS shall so notify GPC. If
GPC notifies NEOTHERAPEUTICS that GPC wishes to assume the prosecution or
maintenance of such J-M Patent Right, NEOTHERAPEUTICS shall exercise its right
to assume such prosecution or maintenance on behalf of GPC, and NEOTHERAPEUTICS
shall assign its rights to such J-M Patent Right in such country to GPC.

      6.5.  TERMINATION OF SUPPORT BY GPC. GPC shall have the right to terminate
its obligations, if any, under this Agreement in any country with respect to any
Patent included in the NEOTHERAPEUTICS Licensed Technology, from time to time,
upon notice to NEOTHERAPEUTICS; provided, however, that no such notice shall be
effective with respect to any such Patent if it is given fewer than sixty (60)
days prior to a deadline for taking any action that must be taken in order to
preserve the owner's rights in such Patent. Upon the delivery of any such
effective notice, GPC's rights, licenses and obligations under this Agreement
with respect to such Patent shall terminate in any such country, except those
obligations that shall have accrued prior to the delivery of such notice.

<PAGE>

7.    GRANT OF LICENSES

      7.1.  EXCLUSIVE SUBLICENSE GRANT. NEOTHERAPEUTICS hereby grants GPC an
exclusive royalty-bearing right and sublicense in the Field throughout the
Territory, with the right to grant further sublicenses in accordance with the
terms of this Agreement, under the J-M Licensed Technology to research, develop,
make, have made, use, sell, offer for sale, have sold, import and export Covered
Products.

      7.2.  EXCLUSIVE LICENSE GRANT. NEOTHERAPEUTICS hereby grants to GPC an
exclusive royalty-bearing right and license in the Field throughout the
Territory, with the right to grant sublicenses in accordance with the terms of
this Agreement, under the NEOTHERAPEUTICS Licensed Technology, the
NEOTHERAPEUTICS Development Technology and NEOTHERAPEUTICS's interest in the
Joint Development Technology to research, develop, make, have made, use, sell,
offer for sale, have sold, import and export Covered Products.

      7.3.  SCOPE OF EXCLUSIVITY. The licenses granted to GPC pursuant to
Sections 7.1 and 7.2 shall be exclusive even as to NEOTHERAPEUTICS, except to
the extent necessary for NEOTHERAPEUTICS to perform its obligations under this
Agreement.

      7.4.  PROVISIONS REGARDING SUBLICENSES. Any sublicense by GPC of the
rights granted to GPC hereunder shall be consistent with the terms of this
Agreement and shall include an obligation for the Sublicensee to comply with the
applicable obligations of GPC set forth in this Agreement. GPC shall provide to
NEOTHERAPEUTICS a copy of any sublicense agreement of the rights granted herein
with any Third Party promptly after entering into such sublicense; provided
that, GPC may redact confidential portions of any such sublicense agreement, but
only to the extent that any such redactions do not impair NEOTHERAPEUTICS'
ability to ensure compliance with the provisions of this Agreement.

      7.5.  TRANSFER OF INFORMATION. Promptly following the Effective Date,
NEOTHERAPEUTICS shall coordinate with the Joint Development Committee and
provide copies of and access to all of LICENSOR'S INFORMATION, LICENSOR'S
ONGOING INFORMATION and all other information relating to the J-M Patent Rights
in its possession. Thereafter, NEOTHERAPEUTICS will continue to provide such
information, as well as NEOTHERAPEUTICS Development Technology, to GPC as it
becomes available to or is conceived by NEOTHERAPEUTICS as soon as practicable
after it becomes available to or is conceived by NEOTHERAPEUTICS.

8.    DEVELOPMENT AND COMMERCIALIZATION

      8.1.  DEVELOPMENT EFFORTS BY GPC. GPC shall, either itself or through its
Affiliates or Sublicensees:

<PAGE>

      (a)   at its own expense, or at the expense of its Affiliates or
Sublicensees, diligently conduct the development of Covered Products within the
Field using Platinum Complexes. GPC shall exercise in the performance of such
development commercially reasonable technical skill and competence;

      (b)   use its commercially reasonable endeavors to obtain appropriate
regulatory approvals for Covered Products in the United States or any of the
countries currently comprising the European Union and Japan and to promote the
distribution and sale of Covered Products in the Field in such countries where
such regulatory approval is obtained;

      (c)   ensure that all literature prepared by GPC and relating to Covered
Products bears an acknowledgement to the effect that they are subject to a
license from J-M and NEOTHERAPEUTICS, and all protocols prepared by GPC and
relating to Covered Products bears an acknowledgement to the effect that they
are subject to a license from NEOTHERAPEUTICS and attach to all Covered Products
a label quoting relevant patent numbers and stating that such Covered Products
are made under license under J-M and NEOTHERAPEUTICS; and

      (d)   advise NEOTHERAPEUTICS promptly of all approvals granted with
respect to Covered Product.

      8.2.  DELEGATION OF IND AUTHORITY; RIGHT TO REFERENCE. NEOTHERAPEUTICS
acknowledges that a Phase II clinical trial of Satraplatin has been conducted
pursuant to an Investigational New Drug Application Number 44,615 filed with the
FDA (the "Filed IND"). Promptly after the Effective Date, NEOTHERAPEUTICS shall
prepare for filing with the FDA all documents necessary to designate and
delegate to GPC all exclusive (even as to NEOTHERAPEUTICS) authority to take
actions and receive all communications from the FDA with respect to the Filed
IND and shall file such documents with the FDA following GPC's review and
approval of such documents. NEOTHERAPEUTICS shall not take any action to revoke
or limit the delegation described in the preceding sentence. In addition, in the
event that the FDA, for any reason, fails to recognize and give full effect to
the delegation described in this Section, NEOTHERAPEUTICS shall not take any
action with respect to the Filed IND or the clinical trials conducted pursuant
to the Filed IND without the prior approval of the Joint Development Committee.
In addition to the foregoing, NEOTHERAPEUTICS hereby grants to GPC an
irrevocable right to reference the Filed IND and all other regulatory
submissions, approvals, clearances, data and other documents and information
related to the Filed IND that NEOTHERAPEUTICS has filed or referenced with the
FDA. Promptly after the Effective Date, the Parties shall begin planning and
coordinating the transfer to the Joint Development Committee of all
responsibilities regarding clinical trials conducted pursuant to the Filed IND.
GPC shall promptly provide to NEOTHERAPEUTICS copies of all correspondence
related to Covered Products delivered to or received from the FDA.

<PAGE>

      8.3.  OWNERSHIP OF REGULATORY FILINGS. Except for the Filed IND, all INDs,
NDAs and other regulatory filings made or filed by GPC with respect to any
Covered Products shall be in the name of, and be owned solely by, GPC.

      8.4.  REPORTING. (a) GPC shall promptly notify NEOTHERAPEUTICS concerning
any happening or circumstance that GPC understands will result in
NEOTHERAPEUTICS's loss of any of its rights under the J-M License Agreement, and
GPC shall reasonably cooperate with NEOTHERAPEUTICS to prevent any such loss.

      (b)   Following any acquisition of or by NEOTHERAPEUTICS (whether through
merger, consolidation, acquisition (directly or indirectly) of stock
representing thirty percent (30%) or more of the outstanding voting stock or
other of its equity securities, sale of all or substantially all of its assets,
or otherwise) by or of any Third Party that is a substantial competitor of GPC,
as determined by objective standards (which shall include, but not be limited
to, a determination as to whether such Third Party is developing or marketing a
drug of the same chemical class as the Covered Product or whether such Third
Party is developing or marketing a drug targeted to the same tumor type as a any
product under development or being marketing by GPC), GPC shall not be required
to include in any report furnished by GPC pursuant to this Agreement, or provide
to any representative of NEOTHERAPEUTICS (or any successor thereto), any
information that GPC, acting in good faith, determines to be competitively
sensitive or enabling information, unless such information is required for
compliance with the obligations to J-M under the J-M License Agreement, in which
event NEOTHERAPEUTICS or its successor, as the case may be, and J-M (if it shall
receive such information) shall execute a nondisclosure agreement, satisfactory
to GPC in form and substance, concerning all such information.

      8.5.  TRADEMARKS. GPC shall market the Covered Products throughout the
Territory under trademarks (collectively, the "Trademarks") selected by GPC. GPC
shall own all right, title and interest in and to such Trademarks and shall bear
all costs and expenses of registering, and maintaining the registration of,
same.

9.    MONETARY OBLIGATIONS

      9.1.  LICENSE FEE. In partial consideration of the rights and licenses
granted to GPC under this Agreement, GPC shall pay to NEOTHERAPEUTICS the
following license fees at the times indicated below:

      (a)   Within ten (10) days after the execution of this Agreement, or such
later date as the First Amendment to the J-M License Agreement shall have been
amended to (x) delete all references in the J-M License Agreement to the form
sub-license agreement attached as Exhibit 1 to the J-M License Agreement and (y)
change the references in Section (7) of the First Amendment to Paragraph 1 of
Article IX in lieu of the references to Paragraph 6 of Article VII, GPC shall
pay NEOTHERAPEUTICS a non-refundable, non-creditable, one-time license fee in
the amount of US$2,000,000 in cash.

<PAGE>

      (b)   Within thirty (30) days of the first dosing of the first patient in
the first Phase III or registrational clinical trial of Satraplatin after the
Effective Date (such date of dosing, the "Dosing Date"), GPC shall pay
NEOTHERAPEUTICS a non-refundable, non-creditable, one time license fee in the
amount of $2,000,000, $1,000,000 of which fee shall be payable in cash and
$1,000,000 of which fee shall be payable through the purchase by GPC, for an
aggregate payment of $1,000,000, of a number of shares of common stock, par
value $.001 per share, of NEOTHERAPEUTICS equal to the lesser of (i) the
quotient obtained by dividing (x) $1,000,000 by (y) one hundred and fifty
percent (150%) of the average closing sale price of the NEOTHERAPEUTICS common
stock, as reported by the Nasdaq quotation system for the twenty (20)
consecutive trading days ending on the third trading day before the Dosing Date,
or (ii) 19.9% of the number of shares of NEOTHERAPEUTICS common stock
outstanding as of the Dosing Date, or such other number of shares as Nasdaq may
specify as the highest number of shares of common stock that NEOTHERAPEUTICS may
issue hereunder without first obtaining stockholder approval (the
"NEOTHERAPEUTICS Shares"); provided that, if the number of NEOTHERAPEUTIC Shares
to be issued pursuant to this Section is determined pursuant to clause (ii)
above, then, until GPC has purchased the number of shares of NEOTHERAPEUTICS
common stock determined pursuant to clause (i) above and subject to
NEOTHERAPEUTICS ability to issue additional shares without first obtaining
stockholder approval pursuant to Nasdaq regulations, all milestone payments owed
by GPC to NEOTHERAPEUTICS pursuant to Section 9.2 below shall be used to
purchase additional shares of NEOTHERAPEUTICS common stock at the price
determined as of the date of the achievement of the applicable milestone in
accordance with the formula set in clause (i)(y) above, and such additional
shares shall be considered to be NEOTHERAPEUTICS Shares hereunder. Concurrently
with the first issuance of the NEOTHERAPEUTICS Shares, the Parties shall execute
a Registration Rights Agreement in the form attached hereto as Exhibit D. GPC
agrees that it shall be a condition of the issuance of the NEOTHERAPEUTICS
Shares that GPC make the representations set forth in Section 2.3 as of the date
of issuance of the NEOTHERAPEUTICS Shares. GPC represents that it has not
engaged in any short selling, option writing, equity swaps, or other types of
hedging transactions or derivative transactions with respect to the common stock
of NEOTHERAPEUTICS, and GPC further agrees that it will not engage in any such
transaction with respect to the common stock of NEOTHERAPEUTICS at any time
during the period commencing on the Effective Date and ending one year after the
issuance of the NEOTHERAPEUTICS Shares.

      9.2.  DEVELOPMENT MILESTONE PAYMENTS BY GPC. (a) In partial consideration
of the rights and licenses granted to GPC by NEOTHERAPEUTICS under this
Agreement, GPC shall pay NEOTHERAPEUTICS the following milestone payments upon
the first occurrence of each event set forth below achieved by GPC or its
Affiliates:

            (i)   US$[Intentionally Redacted] upon acceptance by the FDA of an
      NDA covering Satraplatin;

-----------------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

<PAGE>

            (ii)  US$[Intentionally Redacted] upon acceptance by the EMEA in the
      European Union of an application for marketing clearance covering
      Satraplatin;

            (iii) US$[Intentionally Redacted] upon FDA approval of Satraplatin
      for commercial sale for a first indication;

            (iv)  US$[Intentionally Redacted] upon approval by the EMEA in the
      European Union of Satraplatin for commercial sale for a first indication;

            (v)   US$[Intentionally Redacted] upon first approval by the MHW in
      Japan of Satraplatin for commercial sale;

            (vi)  US$[Intentionally Redacted] upon FDA approval of Satraplatin
      for commercial sale for a second indication; and

            (vii) US$[Intentionally Redacted] upon approval by the EMEA in the
      European Union of Satraplatin for commercial sale for a second indication.

Each of the foregoing payments shall be made within thirty (30) days after
achievement of such milestone. For the avoidance of doubt, after GPC has made
any of the foregoing payments with respect to any one Covered Product, GPC shall
have no further obligation to make such payment with respect to any other
Covered Product. As used in this Section 9.2, "approval" shall mean approval by
the FDA, the EMEA or the MHW of a NDA, MAA or other application for regulatory
approval to market and sell a Covered Product in the United States, the European
Union or Japan, and with respect to the European Union shall also include any
government pricing or reimbursement approval necessary to market or sell such
Covered Product in the European Union.

      9.3.  ROYALTIES. (a) Subject to Section 9.3(b), in partial consideration
of the rights and licenses granted to GPC under this Agreement, GPC shall pay
NEOTHERAPEUTICS a royalty on Net Sales of each Covered Product, commencing on
the First Commercial Sale of each Covered Product by GPC or its Affiliates in
each country in the Territory, in an amount equal to the applicable percentage
of the world-wide Net Sales of such Covered Product by GPC and its Affiliates
throughout the Territory during each calendar year (or portion thereof) during
the term of this Agreement:

            (i)   [Intentionally Redacted]% on worldwide annual Net Sales up to
                  $[Intentionally Redacted]

            (ii)  [Intentionally Redacted]% on worldwide annual Net Sales
                  between $[Intentionally Redacted] and $[Intentionally
                  Redacted]

            (iii) [Intentionally Redacted]% on worldwide annual Net Sales above
                  $[Intentionally Redacted].

--------------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

<PAGE>

Such incremental amounts shall be reduced on a Covered Product by Covered
Product and country by country basis upon the expiration of the J-M Royalty Term
and for the remainder of the Royalty Term by a percentage of Net Sales equal to
[Intentionally Redacted] of the percentage of Net Sales that NEOTHERAPEUTICS had
paid to J-M with respect to sales of such Covered Product immediately prior to
the expiration of the J-M Royalty Term and shall be reduced pro rated
accordingly with respect to any partial calendar year during the term of this
Agreement.

      (b)   Notwithstanding the foregoing, GPC's obligation to make payments
with respect to each Covered Product in each country in the Territory under
Sections 9.3 and 9.4 shall expire upon the expiration of the Royalty Term with
respect to such Covered Product in such country.

      (c)   The obligation to pay royalties to NEOTHERAPEUTICS under this
Section 9.3 is imposed only once with respect to the same unit of a Covered
Product, regardless of the number of Patents pertaining thereto.

      9.4.  SUBLICENSE INCOME.

      (a)   Subject to Section 9.3 (b), GPC shall pay NEOTHERAPEUTICS (i)
[Intentionally Redacted] ([Intentionally Redacted]%) of all Sublicense Fees and
(ii) [Intentionally Redacted] ([Intentionally Redacted]%) of all Sublicense
Royalties received by GPC, provided that, until the expiration of the J-M Royaly
Term, the payments made by GPC to NEOTHERAPEUTICS under clause (ii) shall in any
event not be [Intentionally Redacted] ([Intentionally Redacted]%) of Net Sales
of Covered Products by Sublicensees.

      (b)   Notwithstanding anything else contained herein, upon receipt by GPC
of any payment from a Sublicensee upon the achievement of any applicable
milestone (a "Sublicensee Milestone"), (i) if the Sublicensee Milestone is also
a milestone described in Section 9.2, GPC shall make the applicable milestone
payment under Section 9.2 to NEOTHERAPEUTICS and (ii) the payment received by
GPC from such Sublicensee shall be treated as a Sublicense Fee and subject to
Section 9.4(a), provided that GPC may deduct any payment made pursuant to clause
(i) and all other payments previously made by GPC pursuant to Section 9.2 (to
the extent not previously deducted pursuant to this clause) from such Sublicense
Fee before calculating the percentage owed to NEOTHERAPEUTICS pursuant to
Section 9.4(a) in determining GPC's obligation under such Section. As an
example, if GPC received US$[Intentionally Redacted] from a Sublicensee upon
approval by the EMEA in the European Union of Satraplatin for commercial sale
for a first indication, GPC would pay NEOTHERAPEUTICS US$[Intentionally
Redacted] pursuant to Section 9.2, and US$[Intentionally Redacted]

-------------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

<PAGE>

pursuant to Section 9.4(a) ([Intentionally Redacted]% of US$[Intentionally
Redacted] (US$[Intentionally Redacted] less US$[Intentionally Redacted] paid
pursuant to Section 9.2)), for an aggregate payment of US$[Intentionally
Redacted].

      9.5.  THIRD PARTY PAYMENTS. (a) GPC, at its sole expense, shall pay all
amounts owing to any Third Party to obtain rights to any Valid Claims of any
issued patent or patent application issued to Third Parties determined by the
Joint Development Committee to be necessary for GPC's exercise of its rights
hereunder to research, develop, make, have made, use, sell, offer for sale, have
sold, import or export any Covered Product (collectively, "Third Party
Payments"). Except as provided in Section 9.5(b), GPC shall not be entitled to
any credit under this Agreement on account of any Third Party Payments paid by
GPC.

      (b)   GPC shall be entitled, on a country by country basis, to credit
against payments due to NEOTHERAPEUTICS under this Agreement an amount equal to
the Third Party Payments paid by GPC; provided, however, that the application of
such credit shall not, prior to the expiration of the J-M Royalty Term, reduce
the amounts payable by GPC under this Agreement with respect to any given
calendar quarter to less than a percentage of Net Sales equal to [Intentionally
Redacted] ([Intentionally Redacted]%) above the royalties on Net Sales owed by
NEOTHERAPEUTICS to J-M under the J-M License Agreement and, thereafter, such
credit shall not reduce the amount payable by GPC under this Agreement by more
than [Intentionally Redacted] ([Intentionally Redacted]%). Notwithstanding the
foregoing, if GPC is required to pay an award of damages or a settlement amount
in the form of a reasonable royalty based on sales during any period of previous
infringement (as opposed to the on-going payment of a running royalty), then
such payment shall be allocated to the several calendar quarters during such
period of infringement, and the limits set forth in the previous sentence shall
apply to each portion of such payment allocated to a specific quarter and not to
such payment as a whole.

      9.6.  PAYMENTS UNDER J-M LICENSE. Notwithstanding anything else contained
herein, NEOTHERAPEUTICS shall remain solely responsible to J-M for all payments
due to J-M under the J-M License.

      9.7.  REIMBURSEMENT OF NEOTHERAPEUTICS DEVELOPMENT EXPENSES. Within thirty
(30) days of receipt of invoices from NEOTHERAPEUTICS, which invoices shall be
delivered by NEOTHERAPEUTICS no more frequently than quarterly, GPC shall
reimburse NEOTHERAPEUTICS for all costs and expenses (including full
reimbursement for NEOTHERAPEUTICS personnel) incurred by NEOTHERAPEUTICS in the
development of Covered Products as approved in advance by the Joint Development
Committee.

-------------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

<PAGE>

10.   PAYMENTS AND REPORTS

      10.1. PAYMENT. Except as otherwise provided in this Agreement, all royalty
and other payments due hereunder shall be paid quarterly within thirty (30) days
after the end of each calendar quarter. Each such payment shall be accompanied
by a statement, Covered Product-by-Covered Product and country-by-country, of
the amount of Net Sales during such quarter, the amount of royalties due on such
Net Sales, the amount of Sublicense Fees and Sublicense Royalties during such
quarter and the amount owed to NEOTHERAPEUTICS on account of such Sublicense
Fees and Sublicense Royalties.

      10.2. MODE OF PAYMENT. GPC shall make all payments required under this
Agreement as directed by NEOTHERAPEUTICS from time to time, in U.S. Dollars
(except as provided in Section 10.6). All royalties due hereunder shall first be
determined in the currency of the country in which the Covered Products in
question were sold and then converted into equivalent U.S. funds. The exchange
rate for such conversion shall be that rate quoted in The Wall Street Journal on
the last business day of the applicable reporting period.

      10.3. RECORDS RETENTION. GPC and its Affiliates shall keep complete and
accurate records pertaining to the sale of Covered Products in the Territory in
accordance with the obligations therefor set forth in the J-M License Agreement.

      10.4. AUDIT REQUEST. At the request and expense (except as provided below)
of NEOTHERAPEUTICS, GPC and its Affiliates shall permit an independent,
certified public accountant appointed by NEOTHERAPEUTICS and reasonably
acceptable to GPC, at reasonable times and upon reasonable notice, to examine no
more than once per year those records and all other material documents relating
to or relevant to Net Sales in the possession or control of GPC and its
Affiliates, for a period of three years after such royalties have accrued. The
results of any such examination shall be made available to both Parties. If, as
a result of any inspection of the books and records of GPC or its Affiliates, it
is shown that GPC's royalty payments under this Agreement were less than the
amount which should have been paid, then GPC shall make all payments required to
eliminate any discrepancy revealed by said inspection within forty-five (45)
days after NEOTHERAPEUTICS's demand therefor. Furthermore, if the aggregate
royalty payments GPC made were less than ninety five (95%) of the amount which
should have been paid made during the period in question, GPC shall also
reimburse NEOTHERAPEUTICS for the reasonable out-of-pocket cost of such
inspection and shall pay interest on the deficiency pursuant to Section 10.7.

      10.5. TAXES. In the event that GPC is required to withhold any tax to the
tax or revenue authorities in any country in the Territory in connection with
any payment to NEOTHERAPEUTICS due to the laws of such country which payment is
credited to NEOTHERAPEUTICS's tax liability, such amount shall be deducted from
the royalty or other payment to be made by GPC, and GPC shall notify
NEOTHERAPEUTICS and promptly furnish NEOTHERAPEUTICS with copies of any tax
certificate or other documentation evidencing such withholding. Each Party
agrees to cooperate with the other Party in claiming exemptions from such
deductions or withholdings under any agreement or treaty from time to time in
effect.

<PAGE>

      10.6. BLOCKED CURRENCY. If at any time legal restrictions prevent GPC's
prompt remittance of part or all of the royalties due with respect to any
country where a Covered Product is sold, GPC shall convert the amount owed to
NEOTHERAPEUTICS into U.S. funds and shall pay NEOTHERAPEUTICS directly from
GPC's U.S. source of funds for the amount impounded. GPC shall then pay all
future royalties due to NEOTHERAPEUTICS from GPC's U.S. source of funds so long
as the legal restrictions of this Section 10.6 still apply.

      10.7. LATE PAYMENTS. In the event that any payment GPC is required to make
hereunder is not made within thirty (30) days after such payment was originally
due, GPC shall pay interest on the past due amount as follows:

      (a)   If GPC's late payment pertains to a payment NEOTHERAPEUTICS is
required to make under the J-M License Agreement and causes NEOTHERAPEUTICS to
become liable to pay interest with respect to such payment under the J-M License
Agreement, then GPC shall pay interest on the past due amount as provided under
the applicable provision(s) of the J-M License Agreement.

      (b)   In all other events, GPC shall pay interest on the past due amount
at the rate of twelve percent (12%) per annum, until payment in full is made.

<PAGE>

      11.   MANUFACTURING. Promptly following the Effective Date, GPC and
NEOTHERAPEUTICS shall negotiate in good faith the terms of a Supply Agreement
regarding the supply of PLATINUM COMPLEXES (as defined in the J-M License
Agreement) to GPC, which agreement shall provide for payments to NEOTHERAPEUTICS
equal to [Intentionally Redacted] and shall contain such other terms as are
customary in such an agreement; provided that, nothing shall prevent GPC from
approaching J-M directly to receive PLATINUM COMPLEXES or to receive a grant of
rights to have a Third Party supply PLATINUM COMPLEXES, in which case, GPC shall
pay to NEOTHERAPEUTICS [Intentionally Redacted]. If, despite good faith efforts,
the Parties are unable to agree on the terms of a Supply Agreement within forty
five (45) days of the Effective Date, then the terms of the Supply Agreement
shall be submitted to arbitration pursuant to Section 17.13. Within five (5)
days after both Parties have appointed an arbitrator pursuant to Section 17.13,
each Party shall submit to the panel of arbitrators a form of Supply Agreement
for consideration by the panel; provided that, such forms shall only be for the
panel's consideration, and the panel shall be free to resolve the dispute in any
manner that it deems appropriate. "NEOTHERAPEUTICS's Costs" shall be determined
on a shipment by shipment basis and shall be equal to the amount paid by
NEOTHERAPEUTICS to J-M in accordance with Article VI of the J-M License
Agreement.

12.   CONFIDENTIALITY

      12.1. CONFIDENTIALITY; EXCEPTIONS. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, during the term of this Agreement and for five years thereafter, each
Party, its Affiliates and its Sublicensees, if any (collectively, a "receiving
Party"), shall use their best efforts to keep completely confidential, shall not
publish or otherwise disclose to any Third Party and shall not use for any
purpose other than the performance of this Agreement both the financial terms of
this Agreement and any information furnished to it by the other Party, its
Affiliates or its Sublicensees, if any (collectively, a "disclosing Party") (and
shall ensure that its and its Affiliates' and its Sublicensees' respective
directors, officers, employees or agents do likewise), except to the extent that
it can be established by the receiving Party by competent proof that such
information: (i) is, or hereafter becomes, generally available to the public
other than by reason of any default by the receiving Party with respect to its
confidentiality obligations hereunder; (ii) was already known to the receiving
Party at the time of disclosure by the disclosing Party; (iii) was lawfully
disclosed to the receiving Party by a Third Party who was not in default of any
confidentiality obligation to the disclosing Party; or (iv) is independently
developed by or for the receiving Party without reference to or reliance upon
the information furnished by the disclosing Party (all such information to which
none of the foregoing exceptions applies, "Confidential Information"). The
NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS Development Technology
shall be the Confidential

-------------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

<PAGE>

Information of NEOTHERAPEUTICS and the GPC Development Technology shall be the
Confidential Information of GPC. The Joint Development Technology shall be the
Confidential Information of both Parties.

      12.2. EXCLUSIONS TO CONFIDENTIALITY. The restrictions contained in Section
12.1 shall not apply to any Confidential Information in the hands of a receiving
Party that (i) is submitted by the receiving Party to governmental authorities
to facilitate the issuance of marketing approvals for a Covered Product,
provided that reasonable measures shall be taken to assure confidential
treatment of such information, if practicable; (ii) is provided by GPC to any
Third Party under appropriate terms and conditions, including confidentiality
provisions equivalent to those in this Agreement, for consulting, manufacturing
development, manufacturing, external testing, marketing trials and sublicensing
or potential sublicensing; or (iii) is otherwise required to be disclosed in
compliance with applicable laws or regulations (including, without limitation,
to comply with any governmental or stock exchange disclosure requirements) or an
order by a court or other regulatory body having competent jurisdiction;
provided, however, that if a receiving Party is required to make any such
disclosure of the disclosing Party's Confidential Information such receiving
Party shall, except where impracticable for necessary disclosures (for example
to physicians conducting studies or to health authorities), give reasonable
advance notice to the other Party of such disclosure requirement and, except to
the extent inappropriate in the case of patent applications or otherwise, will
use its best efforts to secure confidential treatment of such Confidential
Information required to be disclosed. In addition, any press release or other
public announcement permitted by the terms of Section 17.7 hereof shall be
excluded from the provisions of Section 12.1.

      12.3. INJUNCTIVE RELIEF. The Parties acknowledge that monetary damages
alone would not adequately compensate the disclosing Party in the event of a
material breach by the receiving Party of this Section 12, and that, in addition
to all other remedies available to the disclosing Party under this Agreement, at
law or in equity, it shall be entitled to injunctive relief for the enforcement
of its rights under this Section 12, without the posting of a bond or other
security.

13.   INTELLECTUAL PROPERTY

      13.1. PATENT ENFORCEMENT. (a) Each Party shall notify the other promptly
after such Party becomes aware of any alleged infringement of any Patent
licensed to GPC under this Agreement in any country in the Territory. Except as
provided in Section 13.3, GPC shall have the first right, but not the duty, to
institute patent infringement actions against Third Parties with respect to any
such alleged infringement. GPC shall take all such actions under this Section
13.1(a) (other than with respect to a Patent included solely in the GPC
Development Technology) in reasonable consultation with NEOTHERAPEUTICS and
shall keep NEOTHERAPEUTICS apprised as to the status of any such infringement
action GPC institutes. NEOTHERAPEUTICS shall execute all reasonable, necessary
and proper documents and take such actions as shall be appropriate to allow GPC
to institute and prosecute infringement actions under this Section 13.1(a).

<PAGE>

      (b)   The costs and expenses of bringing and maintaining any infringement
action under Section 13.1(a) shall be borne solely by GPC.

      (c)   Any award or compensation (including the fair market value of
non-monetary compensation) paid by Third Parties as a result of any infringement
action brought by GPC under Section 13.1(a) (whether by way of settlement or
otherwise) shall be allocated first to reimbursement of GPC for all expenses
incurred by it in connection with such action. Any remaining award or
compensation shall be used to pay NEOTHERAPEUTICS the royalty it would have been
entitled to receive had the balance of such recovery or damages, to the extent
attributable to sales of such infringing products, been attributable to sales of
Covered Products by GPC hereunder.

      (d)   Except as provided in Section 13.3, in the event GPC elects not to,
or fails to, exercise its rights under Section 13.1(a) with respect to any
alleged infringement of a Patent licensed to GPC under this Agreement (excluding
any Patent included solely in the GPC Development Technology) within one hundred
twenty (120) days after receiving notice thereof, NEOTHERAPEUTICS shall have the
right, but not the duty, to institute patent infringement actions against Third
Parties with respect to any such alleged infringement. NEOTHERAPEUTICS shall
take all such actions under this Section 13.1(d) in reasonable consultation with
GPC and shall keep GPC apprised as to the status of any such infringement action
NEOTHERAPEUTICS institutes. GPC shall execute all reasonable, necessary and
proper documents and take such actions as shall be appropriate to allow
NEOTHERAPEUTICS to institute and prosecute infringement actions under this
Section 13.1(d). Any award or compensation (including the fair market value of
non-monetary compensation) paid by Third Parties as a result of any infringement
action brought by NEOTHERAPEUTICS under this Section 13.1(d) (whether by way of
settlement or otherwise) shall be allocated first to reimbursement of
NEOTHERAPEUTICS for all expenses incurred by it in connection with such action.
Any remaining award or compensation shall be allocated equally between the
Parties.

      13.2. INFRINGEMENT ACTIONS BY THIRD PARTIES. (a) Each Party shall notify
the other Party promptly in writing of any claim of, or action for, infringement
of any Patents owned or licensed by Third Parties which is threatened, made or
brought against either Party by reason of either Party's performance of its
obligations under this Agreement or manufacture, use or sale of any Covered
Products in the Territory in the Field.

      (b)   Except as provided in Section 13.3, in the event that such an action
for infringement is commenced solely against a Party or both Parties jointly
and/or any of their respective Affiliates or Sublicensees, as the case may be,
with respect to any Covered Product developed and commercialized by GPC, its
Affiliates and/or Sublicensees, GPC shall defend such action at its own expense,
and NEOTHERAPEUTICS hereby agrees to assist and cooperate with GPC to the extent
necessary in the defense of such suit, in accordance with Section 13.2(c). GPC
shall have the right to settle any such action or consent to an adverse judgment
thereto, and NEOTHERAPEUTICS's consent shall not be required unless such
settlement or consent: (i) imposes any material obligation on NEOTHERAPEUTICS
(including under Section 13.2(d)), or (ii) materially impairs NEOTHERAPEUTICS's
rights in or to any J-
<PAGE>

M Licensed Technology, NEOTHERAPEUTICS Licensed Technology, NEOTHERAPEUTICS
Development Technology and/or Joint Development Technology, in which event
NEOTHERAPEUTICS's consent shall not be unreasonably withheld or delayed.

      (c)   The costs of defending any infringement action with respect to a
Covered Product developed and commercialized by GPC, its Affiliates and/or
Sublicensees shall be borne solely by GPC.

      (d)   During the pendency of any such action, GPC shall continue to pay
all royalties due hereunder. Subject to Section 9.5(b), GPC shall be fully
liable for the payment of any award for damages, or any amount due pursuant to
any settlement entered into by GPC, to the extent that any such action pertains
to a Covered Product developed and commercialized by GPC and/or its Affiliates
or Sublicensees.

      (e)   Except to the extent that the provisions of Section 13.1 shall apply
to any portion thereof, GPC shall retain any award or compensation (including
the fair market value of non-monetary compensation) received by GPC as a result
of any such action (i.e., as a result of a counterclaim).

      13.3. SUPERIOR RIGHTS OF J-M. Notwithstanding any other provision of this
Agreement, the Parties' respective rights and obligations under this Section 13
shall be subject, in all events, to any superior rights of J-M under the J-M
License Agreement regarding the J-M Licensed Technology.

14.   INDEMNIFICATION

      14.1. BY GPC. GPC shall indemnify and hold NEOTHERAPEUTICS and its
Affiliates and their respective directors, officers, employees and agents,
harmless from and against any and all liabilities, damages, losses, costs and
expenses (including the reasonable fees of attorneys and other professionals and
other reasonable litigation expenses) arising out of or resulting from:

            (i)   the negligence, recklessness or intentional misconduct of GPC,
      its Affiliates or its Sublicensees and their respective directors,
      officers, employees and agents, in connection with the work performed by
      GPC in connection with the development of Covered Products or pursuant to
      Section 8 or in connection with GPC's exercise of any of its rights
      hereunder;

            (ii)  any and all product liability claims resulting from the
      development and/or commercialization of any Covered Product by GPC, its
      Affiliates or its Sublicensees;

            (iii) any warranty claims, Covered Product recalls or any tort
      claims of personal injury (including death) or property damage relating to
      or arising out of the manufacture, use, distribution or sale of any
      Covered Product by GPC, its Affiliates or its Sublicensees due to any
      negligence, recklessness or intentional

<PAGE>

      misconduct by, or strict liability of, GPC, its Affiliates or its
      Sublicensees, and their respective directors, officers, employees and
      agents, except, in each case, to the comparative extent such claim arose
      out of or resulted from the negligence, recklessness or intentional
      misconduct of NEOTHERAPEUTICS or its Affiliates and their respective
      directors, officers, employees and agents; or

            (iv)  any breach of any representation or warranty made by GPC in
      Section 2.1.

      14.2. BY NEOTHERAPEUTICS. NEOTHERAPEUTICS shall indemnify and hold GPC,
its Affiliates and its Sublicensees and their respective directors, officers,
employees and agents, harmless from and against any and all liabilities,
damages, losses, costs and expenses (including the reasonable fees of attorneys
and other professionals and other reasonable litigation expenses) arising out of
or resulting from:

            (i)   the negligence, recklessness or intentional misconduct of
      NEOTHERAPEUTICS or its Affiliates and their respective directors,
      officers, employees and agents, in connection with the work performed by
      NEOTHERAPEUTICS under the development of Covered Products or pursuant to
      Section 5 or in connection with NEOTHERAPEUTICS's exercise of any of its
      rights hereunder; or

            (ii)  any breach of any representation or warranty made by
      NEOTHERAPEUTICS pursuant to Section 2 or 3.1.

      14.3. NOTICE. In the event that any Person entitled thereto (an
"Indemnitee") is seeking indemnification under Section 14.1 or 14.2, such
Indemnitee shall inform the indemnifying Party of a claim as soon as reasonably
practicable after the indemnitee receives notice of the claim, shall permit the
indemnifying Party to assume direction and control of the defense of the claim
(including the sole right to settle it at the sole discretion of the
indemnifying Party, provided that such settlement does not impose any material
obligation on the indemnitee or the other Party) and shall cooperate as
requested (at the expense of the indemnifying Party) in the defense of the claim
(including, without limitation, granting the indemnifying Party limited access
to pertinent records and making persons under such Indemnitee's control
available for interview and testimony).

      14.4. COMPLETE INDEMNIFICATION. As the Parties intend complete
indemnification, all costs and expenses incurred by any Indemnitee to enforce
this Section 14 shall be reimbursed by the indemnifying Party.

15.   TERM; TERMINATION

      15.1. TERM. This Agreement shall commence as of the Effective Date and,
unless sooner terminated as provided hereunder, shall expire as follows:

      (a)   As to each Covered Product in each country in the Territory, this
Agreement shall expire upon the expiration of the Royalty Term with respect to
such Covered Product in such country.

<PAGE>

      (b)   This Agreement shall expire in its entirety upon the termination of
the respective Royalty Terms with respect to all Covered Products in all
countries in the Territory.

      15.2. EFFECT OF EXPIRATION. Following the expiration of this Agreement
with respect to a Covered Product in a country in the Territory pursuant to
Section 15.1(a), GPC shall have the royalty-free, perpetual right to continue to
make, have made, use, sell, offer for sale, have sold and export such Covered
Product in such country. Following the expiration of the term of this Agreement
in its entirety pursuant to Section 15.1(b), GPC shall have the royalty-free,
perpetual right to continue to make, have made, use, sell, offer for sale, have
sold and export all Covered Products in all countries in the Territory.

      15.3. TERMINATION BY EITHER PARTY. Each Party shall have the right to
terminate this Agreement, upon notice to the other Party, in the event that:

            (i)   Such other Party materially defaults with respect to any of
      its material obligations under this Agreement and does not cure such
      default within sixty (60) days after the receipt of a notice from the
      non-breaching Party specifying the nature of, and requiring the remedy of,
      such default (or, if such default cannot be cured within such sixty
      (60)-day period, if the breaching Party does not commence and diligently
      continue actions to cure same during such sixty (60)-day period); provided
      that, (x) if NEOTHERAPEUTICS is the Party claiming a default by GPC, GPC
      shall promptly following receipt of such notice of default notify
      NEOTHERAPEUTICS if it intends to seek to cure such default, (y) if the
      default relates to the payment of any amounts owed under this Agreement,
      the cure period described above shall be fifteen (15) days from receipt of
      notice of such default, and (z) if any such default is limited to the
      breaching Party's obligations with respect to a particular Covered Product
      and/or a particular country in the Territory, then any termination of this
      Agreement under this clause (i) due to such default shall be limited to
      the breaching Party's rights under this Agreement with respect to such
      Covered Product and/or country. Any termination pursuant to this clause
      (i) shall be without prejudice to any of the non-breaching Party's other
      rights under this Agreement, and in addition to any other remedies
      available to it by law or in equity;

            (ii)  The other Party shall have: (i) voluntarily commenced any
      proceeding or filed any petition seeking relief under the bankruptcy,
      insolvency or other similar laws of any jurisdiction, (ii) applied for, or
      consented to, the appointment of a receiver, trustee, custodian,
      sequestrator, conciliator, administrator or similar official for it or for
      all or substantially all of its property, (iii) filed an answer admitting
      the material allegations of a petition filed against or in respect of it
      in any such proceeding, (iv) made a general assignment for the benefit of
      creditors of all or substantially all of its assets, (v) admitted in
      writing its inability to pay all or substantially all of its debts as they
      become due, or (vi) taken corporate action for the purpose of effecting
      any of the foregoing; or

<PAGE>

            (iii) An involuntary proceeding shall have been commenced, or any
      involuntary petition shall have been filed, in a court of competent
      jurisdiction seeking: (i) relief in respect of the other Party, or of its
      property, under the bankruptcy, insolvency or similar laws of any
      jurisdiction, (ii) the appointment of a receiver, trustee, custodian,
      sequestrator, conciliator, administrator or similar official for such
      other Party or for all or substantially all of its property, or (iii) the
      winding-up or liquidation of such other Party; and, in each case, such
      proceeding or petition shall have continued undismissed for sixty (60)
      days, or an order or decree approving or ordering any of the foregoing
      shall have continued unstayed, unappealed and in effect for thirty (30)
      days.

      15.4. TERMINATION BY GPC. Notwithstanding any other provision of this
Agreement, GPC shall have the right to terminate this Agreement, in its entirety
or with respect to any particular Covered Product and/or country in the
Territory, at any time upon six (6) months' notice (or less, at NEOTHERAPEUTICS
discretion) to NEOTHERAPEUTICS.

      15.5. EFFECT OF EXPIRATION OR TERMINATION. (a) Subject to Section 15.5(b),
upon any termination of this Agreement by NEOTHERAPEUTICS pursuant to Section
15.3 or by GPC pursuant to Section 15.4, GPC shall (i) transfer and assign to
NEOTHERAPEUTICS all of GPC's right, title and interest in and to any GPC
Development Technology and all data, reports, records, materials and other
intellectual property owned or controlled by GPC that relates exclusively to the
Covered Products; (ii) grant NEOTHERAPEUTICS a non-exclusive license, solely for
the purpose of NEOTHERAPEUTICS's developing, making, having made, using,
marketing and selling Covered Products, under GPC's interest in any Joint
Development Technology that does not exclusively relate to the Covered Products;
and (iii) transfer and assign to NEOTHERAPEUTICS ownership of all INDs, NDAs and
other regulatory filings made or filed with respect to any Covered Product (or,
if such transfer and assignment is not permitted under the laws of any
applicable jurisdiction, GPC shall take such other permitted actions with
respect to such filings as may be reasonably requested by NEOTHERAPEUTICS), all
upon commercially reasonable, arms length financial terms and conditions that
the Parties shall negotiate in good faith and agree upon as soon as practicable
after such termination of this Agreement; provided that, if this Agreement is
terminated by GPC pursuant to Section 15.4, then NEOTHERAPEUTICS shall not be
obligated to pay any amount for the licenses and transfers described in this
sentence. In the event the Parties, despite the mutual use of good faith
efforts, are unable to agree upon such terms and conditions, the Parties shall
appoint an independent valuation expert who shall determine such terms and
conditions, which determination shall be binding upon the Parties. If the
Parties are unable to agree upon the appointment of such an expert, then each
Party shall nominate an expert (the cost of whom shall be borne by such Party),
and both experts appointed by the Parties shall jointly appoint the expert who
shall make such determination. Any expert appointed pursuant to this Section
15.5(a) shall have at least fifteen (15) years' experience in the business of
pharmaceutical development and commercialization. Except as provided above, the
costs and expenses of any expert acting under this Section 15.5(a) shall be
borne equally by the Parties.

<PAGE>

      (b)   Notwithstanding the foregoing:

      (i)   In the event of any termination of this Agreement by NEOTHERAPEUTICS
pursuant to Section 15.3 or by GPC pursuant to Section 15.4 with respect to
fewer than all of the Covered Products and/or fewer than all of the countries in
the Territory, the rights, licenses and other benefits to be transferred,
granted and otherwise assigned to NEOTHERAPEUTICS under Section 15.5(a) shall be
expressly limited to those pertaining to the Covered Products and/or the
countries in the Territory to which such termination applies; and

      (ii)  At any time prior to any transfer, granting and assignment of
rights, licenses and benefits to NEOTHERAPEUTICS pursuant to Section 15.5(a),
NEOTHERAPEUTICS may elect, upon notice to GPC, to waive the application of
Section 15.5(a) with respect to such rights, licenses and benefits. Following
any such waiver neither Party shall have any obligation or liability to the
other with respect to such rights, licenses and benefits.

      15.6. RIGHT TO SELL STOCK ON HAND. Provided that GPC is not in material
breach of any obligation under this Agreement at the time of any termination of
this Agreement, in whole or in part, GPC shall have the right for one year
thereafter to dispose of all Covered Product then in its inventory and to
complete manufacture of and dispose of any work-in-progress then being
manufactured, as though this Agreement had not terminated. GPC shall pay
royalties thereon, in accordance with the provisions of this Agreement, as
though this Agreement had not terminated.

      15.7. SURVIVAL OF SUBLICENSES. Upon any termination of this Agreement, all
sublicenses granted by GPC under this Agreement shall be automatically assigned
to NEOTHERAPEUTICS, which shall thereafter receive all benefits and have all
obligations under the sublicenses as in the place and stead of GPC.

      15.8. EFFECT OF TERMINATION OF J-M LICENSE AGREEMENT. Upon any termination
of the J-M License Agreement, GPC shall attorn to and accept J-M in place of
NEOTHERAPEUTICS such that this Agreement shall be deemed to be an agreement
between J-M and GPC.

      15.9. ACCRUED RIGHTS, SURVIVING OBLIGATIONS. (a) Termination,
relinquishment or expiration of this Agreement for any reason shall be without
prejudice to any rights which shall have accrued to the benefit of either Party
prior to such termination, relinquishment or expiration. Such termination,
relinquishment or expiration shall not relieve either Party from obligations
which are expressly indicated to survive termination or expiration of this
Agreement. The rights of the Parties upon termination described in this
Agreement shall not be exclusive of any other rights or claims at law or in
equity that either Party may have against the other arising out of this
Agreement.

      (b)   Termination, relinquishment or expiration of this Agreement shall
not terminate each Party's obligation to pay all royalties, milestone payments
and other monetary obligations that may have accrued hereunder prior to such
termination. All of

<PAGE>

the Parties' rights and obligations under Sections 6.1, 6.2, 8.5, 10, 12, 13
(solely with respect to actions pending at such time), 14, 15.2, 15.5, 15.6,
15.7, 15.8, 15.9, 17.1 (if in effect at such time), 17.3, 17.5, 17.12, 17.13 and
17.14 shall survive termination, relinquishment or expiration hereof.

16.   FORCE MAJEURE

      Neither Party shall be held liable or responsible to the other Party nor
be deemed to be in default under or in breach of any provision of this Agreement
for failure or delay in fulfilling or performing any obligation under this
Agreement when such failure or delay is due to force majeure, and without the
fault or negligence of the Party so failing or delaying. For purposes of this
Agreement, force majeure shall be defined as causes beyond the control of the
Party, including, without limitation, acts of God; acts, regulations, or laws of
any government; war; civil commotion; destruction of production facilities or
materials by fire, flood, earthquake, explosion or storm; labor disturbances;
epidemic; and failure of public utilities or common carriers. In such event
NEOTHERAPEUTICS or GPC, as the case may be, shall immediately notify the other
Party of such inability and of the period for which such inability is expected
to continue. The Party giving such notice shall thereupon be excused from such
of its obligations under this Agreement as it is thereby disabled from
performing for so long as it is so disabled and for thirty (30) days thereafter.
To the extent possible, each Party shall use reasonable efforts to minimize the
duration of any force majeure.

17.   MISCELLANEOUS

      17.1. RELATIONSHIP OF PARTIES. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employment or joint venture
relationship between the Parties. Neither Party shall be entitled to, or shall,
incur any debts or make any commitments for the other, except to the extent, if
at all, specifically provided herein.

      17.2. ASSIGNMENT. (a) Each Party shall be entitled to assign this
Agreement to any of its Affiliates upon sixty (60) days' prior written notice to
the other Party; provided, however, that in the event of any such assignment,
the assigning Party shall remain jointly and severally liable with respect to
all of its obligations hereunder, and in the event of any default relating to
any such obligations, the other Party shall be entitled to proceed against
either such Affiliate or directly against the assigning Party, as such other
Party may determine in its sole discretion, to enforce this Agreement.

      (b)   Except as provided in Section 17.5(a), neither Party shall be
entitled to assign its rights hereunder without the express written consent of
the other Party, except that each Party may assign this Agreement to any
assignee of all or substantially all of such Party's business (or that portion
thereof to which this Agreement relates) or in the event of such Party's merger,
consolidation or similar transaction.

      (c)   No assignment contemplated by this Section 17.3 shall be valid or
effective unless and until the assignee/transferee shall agree in writing to be
bound by the provisions of this Agreement.

<PAGE>

      17.3. DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN SECTIONS 2
AND 3.1, THE PARTIES EXPRESSLY DISCLAIM ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY RIGHTS, OR ARISING FROM
A COURSE OF DEALING OR USAGE OF TRADE PRACTICE.

      17.4. FURTHER ACTIONS. Each Party shall execute, acknowledge and deliver
such further instruments, and take all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

      17.5. NOTICE. Any notice or request required or permitted to be given
under or in connection with this Agreement shall be deemed to have been
sufficiently given if in writing and personally delivered or sent by certified
mail (return receipt requested), facsimile transmission (receipt verified), or
overnight express courier service (signature required), prepaid, to the Party
for which such notice is intended, at the address set forth for such Party
below:

      (i)   In the case of GPC, to:

               GPC BIOTECH AG
               Fraunhoferstrasse 20
               D-82152 Martinsried/Munich
               Germany

               Attention: Chief Executive Officer
               Facsimile No.: 011-49-89-8565-2610

      With a copy to:

               Ropes & Gray
               One International Place
               Boston, Massachusetts
               USA
               Attention: Marc A. Rubenstein, Esq.
               Facsimile No.: 617-951-7050

      (ii)  In the case of NEOTHERAPEUTICS, to:

               157 Technology Drive
               Irvine, California 92618
               USA
               Attention:
               Facsimile No.: 949-788-6706

<PAGE>

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon actual receipt thereof. If delivered personally or by
facsimile transmission, the date of delivery shall be deemed to be the date on
which such notice or request was given. If sent by overnight express courier
service, the date of delivery shall be deemed to be the next business day after
such notice or request was deposited with such service. If sent by certified
mail, the date of delivery shall be deemed to be the fifth (5th) business day
after such notice or request was deposited with the postal service in the
country of mailing.

      17.6. USE OF NAME. Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party (including, without limitation, any Trademark) for any purpose in
connection with the performance of this Agreement.

      17.7. PUBLIC ANNOUNCEMENTS. (a) Except as required by law (including,
without limitation, the applicable disclosure requirements of any relevant
regulatory authority or stock exchange) and as permitted by Section 12.2,
neither Party shall make any public announcement concerning this Agreement, any
Covered Product or any other subject matter hereof without the prior written
consent of the other Party, which shall not be unreasonably withheld or delayed.
It shall not be unreasonable for a Party to withhold consent with respect to any
public announcement containing any of such Party's Confidential Information. In
the event of any required or proposed public announcement, (i) the Parties shall
consult with each other in good faith as to the timing thereof, and (ii) the
Party making such announcement shall provide the other Party with a copy of the
proposed text prior to such announcement sufficiently in advance of the
scheduled release of such announcement to afford such other Party a reasonable
opportunity to review and comment upon the proposed text. Notwithstanding the
foregoing, the Parties agree to prepare a mutually agreeable press release that
may be used by either Party in connection with this Agreement, and any further
announcement containing substantially the same information may be used without
the need to seek the consent of the other Party.

      (b)   Each Party acknowledges and agrees that the other Party needs to
communicate with its investors regularly and keep them apprised of the
development status of the products in which such Party has an interest. In order
to facilitate this communication, promptly after the Effective Date each Party
shall designate, from time to time, one employee who shall have primary
responsibility for reviewing and approving all proposed investor communications
of the other Party, to the extent that they pertain to this Agreement, any
Covered Product or any other subject matter hereof. Each Party shall instruct
such employee to review the content of such draft communications as
expeditiously as possible and otherwise to cooperate with and assist the other
Party in connection therewith, so long as the number of such communications and
the timing thereof are reasonable.

      (c)   Following a Party's consent to or approval of the public
announcement of any information pursuant to this Section 17.7, both Parties
shall be entitled to make subsequent public announcements of such information
without renewed compliance with this Section 17.7, unless the scope and/or
duration of such consent or approval is expressly limited.

<PAGE>

      17.8. WAIVER. A waiver by either Party of any of the terms and conditions
of this Agreement in any instance shall not be deemed or construed to be a
waiver of such term or condition for the future, or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall be cumulative, and none of them shall be in limitation
of any other remedy, right, undertaking, obligation or agreement of either
Party.

      17.9. COMPLIANCE WITH LAW. Nothing in this Agreement shall be deemed to
permit a Party to export, re-export or otherwise transfer any Covered Product
sold under this Agreement without compliance with applicable laws.

      17.10. SEVERABILITY. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision shall be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement.

      17.11. AMENDMENT. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

      17.12. GOVERNING LAW; ENGLISH ORIGINAL; JURISDICTION. (a) This Agreement
shall be governed by and interpreted in accordance with the laws of the
Commonwealth of Massachusetts without regard to its choice of law principles.
The English original of this Agreement shall prevail over any translation
hereof.

      (b)   Without prejudice to the rights and obligations of the Parties under
Section 17.13, each Party hereby consents to the in personam jurisdiction of any
state or federal court sitting in the Commonwealth of Massachusetts with respect
to any matter arising in connection with this Agreement and further consents to
the service of any process, notice of motion or other application to any such
court or a judge thereof outside the Commonwealth of Massachusetts by registered
or certified mail or personal service, provided that reasonable time is allowed
for appearance. Each Party hereby waives, to the greatest extent it may do so,
any defense it may have on the grounds of inconvenient forum with respect to any
action or proceeding maintained in any state or federal court in Massachusetts.

      17.13. ARBITRATION. (a) Any dispute arising out of or relating to any
provisions of this Agreement shall be finally settled by arbitration to be held
in Boston, Massachusetts, under the auspices and then current commercial
arbitration rules of the American Arbitration Association (the "AAA"). Such
arbitration shall be conducted by three (3) arbitrators. Within thirty (30) days
after the commencement of any arbitration, each Party shall appoint one
arbitrator, and these two arbitrators shall jointly appoint the third
arbitrator, who shall have significant experience in pharmaceutical drug

<PAGE>

development and commercialization; provided, however, that if the two
arbitrators appointed by the Parties are unable to agree upon the third
arbitrator within thirty (30) days after their appointment, then the third
arbitrator shall be appointed by the AAA. The Parties shall instruct such
arbitrators to render a determination of any such dispute within four (4) months
after their appointment. All arbitration proceedings shall be conducted in
English. Judgment upon any award rendered may be entered in any court having
jurisdiction, or application may be made to such court for a judicial acceptance
of the award and an order of enforcement, as the case may be.

      (b)   Section 17.14(a) shall not prohibit a Party from seeking injunctive
relief from a court of competent jurisdiction in the event of a breach or
prospective breach of this Agreement by the other Party which would cause
irreparable harm to the first Party.

      17.14. NO CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY OR ANY OF
ITS RESPECTIVE AFFILIATES OR SUBLICENSEES BE LIABLE TO THE OTHER PARTY OR ANY OF
ITS AFFILIATES OR SUBLICENSEES FOR SPECIAL, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT
LIABILITY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR
REVENUE, OR CLAIMS OF CUSTOMERS OF ANY OF THEM OR OTHER THIRD PARTIES FOR SUCH
OR OTHER DAMAGES.

      17.15. ENTIRE AGREEMENT. This Agreement (together with the Exhibits
hereto) sets forth the entire agreement and understanding between the Parties as
to the subject matter hereof and merges all prior discussions and negotiations
between them, and neither of the Parties shall be bound by any conditions,
definitions, warranties, understandings or representations with respect to such
subject matter other than as expressly provided herein or as duly set forth on
or subsequent to the Effective Date in writing and signed by a proper and duly
authorized officer or representative of the Party to be bound thereby. Without
limiting the generality of the foregoing, the terms and conditions of this
Agreement shall supersede the terms and conditions of any confidentiality,
non-disclosure or similar such agreement that the Parties may have executed
prior to the Effective Date.

      17.16. PARTIES IN INTEREST. All the terms and provisions of this Agreement
shall be binding upon, inure to the benefit of and be enforceable by the Parties
hereto and their respective permitted successors and assigns.

      17.17. DESCRIPTIVE HEADINGS. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

      17.18. COUNTERPARTS. This Agreement may be executed simultaneously in two
counterparts, any one of which need not contain the signature of more than one
Party, but both such counterparts taken together shall constitute one and the
same agreement.

<PAGE>

            IN WITNESS WHEREOF, each of the Parties has caused this Agreement to
be executed by its duly authorized officer as of the day and year first above
written.

                                  NEOTHERAPEUTICS, INC.

                                  By: /s/ Rajesh Shrotriya
                                      ---------------------------------
                                  Name:  Rajesh C. Shrotriya, M.D.
                                  Title: Chairman, CEO & President

                                  GPC BIOTECH AG

                                  By: /s/ Bernd R. Seizinger
                                      ---------------------------------
                                  Name:  Bernd R. Seizinger
                                  Title: Chief Executive Officer

                                  By: /s/ S. Meier-Ewert
                                      ---------------------------------
                                  Name: S. Meier-Ewert
                                  Title: Chief Scientific Officer

<PAGE>

                                    EXHIBIT A

                              J-M License Agreement

The Johnson Matthey PLC License Agreement was filed as Exhibit 10.5 to Form
10-Q, as filed with the Securities and Exchange Commission on November 14, 2001,
and incorporated herein by this reference.

The First Amendment to the License Agreement dated August 28, 2001 between
Johnson Matthey PLC and NeoTherapeutics, Inc. dated September 30, 2002, is filed
as Exhibit 10.8 to this Form 10-Q and incorporated herein by this reference.

<PAGE>

                                    EXHIBIT B

                                  Patent Rights

Filed as Schedule A of Exhibit 10.5 to Form 10-Q, as filed with the Securities
and Exchange Commission on November 14, 2001, and incorporated herein by this
reference.

<PAGE>

                                    EXHIBIT C

                 Initial Members of Joint Development Committee

         GPC Designees:           Marcel Rozencweig, Chairman
                                  Michael Petrone
                                  Ed McNiff

         NEOTHERAPEUTICS
         Designees:               Gino Lenaz
                                  Ashok Gore
                                  Shanta Chawla

<PAGE>

                                    EXHIBIT D

                              NEOTHERAPEUTICS, INC.

                          REGISTRATION RIGHTS AGREEMENT

      This Registration Rights Agreement (this "Agreement") is made as of
_______ __, 2002, between NeoTherapeutics, Inc., a Delaware corporation (the
"Company"), and GPC Biotech AG, a company organized under the laws of the
Federal Republic of Germany (the "GPC").

                                    RECITALS

      The Company and GPC are parties to a Co-Development and License Agreement
(the "License Agreement") dated as of September __, 2002, pursuant to which the
Company has agreed to sell to GPC and GPC has agreed to purchase from the
Company shares of the Company's Common Stock, upon the attainment of certain
milestones under the License Agreement. As a condition to GPC's obligation to
purchase shares of Common Stock under the License Agreement, the Company and GPC
are required to enter into this Agreement in order to provide GPC with certain
rights to register for resale the shares of the Company's Common Stock purchased
under the License Agreement.

                                    AGREEMENT

      The parties agree as follows:

1.    DEFINITIONS; REGISTRATION RIGHTS.

      1.1   DEFINITIONS. For purposes of this Agreement:

            (a)   "Common Stock" means the common stock, par value $0.001 per
share, of the Company.

            (b)   "Exempt Registration" means a registration statement relating
to the sale of securities by the Company pursuant to a stock option, stock
purchase or similar benefit plan or an SEC Rule 145 transaction or any other
registration statement that would not customarily provide for the secondary sale
of equity shares for cash.

            (c)   "Holder" means (i) GPC and (ii) any person owning Registrable
Securities to whom the rights under this Section 1 have been transferred in
accordance with Section 1.9 of this Agreement.

            (d)   "person" means any individual, corporation, partnership,
limited liability company, trust, business, association or government or
political subdivision thereof, governmental agency or other entity.

            (e)   "register," "registered," and "registration" refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the Securities Act and the declaration or
ordering of effectiveness of such registration statement or document.

<PAGE>

            (f)   The term "Registrable Securities" means (i) the shares of
Common Stock issued under the License Agreement, and (ii) any other shares of
Common Stock of the Company issued as (or issuable upon the conversion or
exercise of any warrant, right or other security which is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of,
the shares listed in clause (i) and this clause (ii); provided, however, that
the foregoing definition shall exclude in all cases any Registrable Securities
sold or transferred by a Holder in a transaction in which such Holder's rights
under this Agreement are not assigned. Notwithstanding the foregoing, securities
shall only be treated as Registrable Securities if and so long as they have not
been (A) sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, or (B) sold in a transaction
exempt from the registration and prospectus delivery requirements of the
Securities Act under Section 4(1) thereof so that all transfer restrictions, and
restrictive legends with respect thereto, if any, are removed upon the
consummation of such sale.

            (g)   "SEC" means the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act.

            (h)   "Securities Act" means the Securities Act of 1933, as amended.

      1.2   COMPANY REGISTRATION.

            (a)   Initiation. If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected
by the Company for stockholders other than the Holders) any of its stock in
connection with the public offering of such securities solely for cash (other
than an Exempt Registration), the Company shall, at such time, promptly give
each Holder notice of such proposed registration. Upon the written request of
each Holder given within 20 days after receipt by such Holder of the Company's
notice, the Company shall, subject to the provisions of Section 1.2(b), cause to
be registered all of the Registrable Securities that each such Holder has
requested to be registered.

            (b)   Underwritten Offering. In connection with any offering
involving an underwriting of shares of the Company's capital stock, the Company
shall not be required under Section 1.2(a) to include any of the Holders'
securities in such underwriting unless they accept the terms of the underwriting
as agreed upon between the Company and the underwriters selected by it (or by
other persons entitled to select the underwriters), and then only in such
quantity as the underwriters determine in their sole discretion will not
jeopardize the success of the offering by the Company. If the total amount of
securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the amount of securities sold other than by
the Company that the underwriters determine in their sole discretion is
compatible with the success of the offering, then the Company shall be required
to include in the offering only that number of such securities, including
Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering (the securities so
included to be apportioned pro rata (to the nearest 100 shares) among the
selling stockholders according to the total amount of securities entitled to be
included therein owned by each selling

<PAGE>

stockholder or in such other proportions as shall mutually be agreed to by such
selling stockholders). For purposes of the preceding apportionment, for any
participating Holder that is a partnership, limited liability company or
corporation, the partners, retired partners, members, retired members and
stockholders of such Holder, or the estates and family members of any such
partners, members, retired partners or members and any trusts for the benefit of
any of the foregoing persons shall be deemed to be a single "selling
stockholder," and any pro-rata reduction with respect to such "selling
stockholder" shall be based upon the aggregate amount of shares carrying
registration rights owned by all Persons included in such "selling stockholder,"
as defined in this sentence.

            (c)   Right to Terminate Registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this
Section 1.2 prior to the effectiveness of such registration whether or not any
Holder has elected to include Registrable Securities in such registration.

      1.3   OBLIGATIONS OF THE COMPANY. Whenever required under this Section 1
to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:

            (a)   Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective.

            (b)   Prepare and file with the SEC such amendments and supplements
to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the
Securities Act.

            (c)   Furnish to the Holders such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
Securities Act, and such other documents as they may reasonably request in order
to facilitate the disposition of such Registrable Securities.

            (d)   Use its reasonable best efforts to register and qualify the
securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Holders, provided that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions.

            (e)   In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement with the managing
underwriter of such offering in usual and customary form and consistent with the
other provisions of this Agreement. Each Holder participating in such
underwriting shall also enter into and perform its obligations under such an
agreement.

            (f)   Promptly notify each Holder covered by the registration
statement at any time when the Company becomes aware of the happening of any
event as a result of which the registration statement or the prospectus included
in such registration statement or any supplement to the prospectus (as then in
effect) contains any untrue statement of a material fact

<PAGE>

or omits to state a material fact necessary to make the statements there in (in
the case of the prospectus, in light of the circumstances under which they were
made) not misleading or, if for any other reason it shall be necessary during
such time period to amend or supplement the registration statement or the
prospectus in order to comply with the Securities Act, whereupon, in either
case, each Holder shall immediately cease to use such registration statement or
prospectus for any purpose and, as promptly as practicable thereafter, the
Company shall prepare and file with the SEC, and furnish without charge to the
appropriate Holders and managing underwriters, if any, a supplement or amendment
to such registration statement or prospectus which will correct such statement
or omission or effect such compliance and such copies thereof as the Holders and
any underwriters may reasonably request.

            (g)   Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange or market on which similar
securities issued by the Company are then listed or traded, if applicable.

            (h)   Use its reasonable best efforts to furnish, at the request of
any Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this Section
1, if such securities are being sold through underwriters, or, if such
securities are not being sold through underwriters, on the date that the
registration statement with respect to such securities becomes effective, (i) an
opinion, dated such date, of the counsel representing the Company for the
purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering, addressed to the underwriters,
if any, and to the Holders requesting registration of Registrable Securities and
(ii) a letter dated such date, from the independent certified public accountants
of the Company, in form and substance as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities (to the extent the then applicable
standards of professional conduct permit said letter to be addressed to the
Holders).

      1.4   FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities.

      1.5   EXPENSES OF REGISTRATION. All expenses other than underwriting
discounts and commissions incurred in connection with registrations initiated
pursuant to Section 1.2, including without limitation all registration, filing
and qualification fees, printers' and accounting fees, fees and disbursements of
counsel for the Company and the reasonable fees and disbursements of one counsel
for the Holders, shall be borne by the Company.

      1.6   DELAY OF REGISTRATION. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 1.

<PAGE>

      1.7   INDEMNIFICATION. In the event any Registrable Securities are
included in a registration statement under this Section 1:

            (a)   Indemnification by the Company. To the extent permitted by
law, the Company will indemnify and hold harmless each Holder, any underwriter
(as defined in the Securities Act) for such Holder and each person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), against
any losses, claims, damages, or liabilities (joint or several) to which they may
become subject under the Securities Act, the Exchange Act or other federal or
state law, insofar as such losses, claims, damages, or liabilities (or actions
in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (collectively a "Violation"): (i) any untrue
statement or alleged untrue statement of a material fact contained in such
registration statement, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state therein a material fact required to be stated therein,
or necessary to make the statements therein not misleading, or (iii) any
violation or alleged violation by the Company of the Securities Act, the
Exchange Act, any state securities law or any rule or regulation promulgated
under the Securities Act, the Exchange Act or any state securities law; and the
Company will pay to each such Holder, underwriter or controlling person, as
incurred, any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this
Section 1.7(a) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability, or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable to any Holder, underwriter or controlling person for
any such loss, claim, damage, liability, or action to the extent that it arises
out of or is based upon a Violation (x) which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by any such Holder, underwriter or controlling person or
(y) which occurs in any preliminary prospectus if a final, amended or
supplemental prospectus which corrects such Violation is delivered by the
Company to such person at or prior to the written confirmation of the sale
giving rise to such loss, claim, damage, liability, or action.

            (b)   Indemnification by the Holders. To the extent permitted by
law, each selling Holder will indemnify and hold harmless the Company, each of
its directors, each of its officers who has signed the registration statement,
each person, if any, who controls the Company within the meaning of the
Securities Act, any underwriter, any other Holder selling securities in such
registration statement and any controlling person of any such underwriter or
other Holder, against any losses, claims, damages, or liabilities (joint or
several) to which any of the foregoing persons may become subject, under the
Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereto) arise
out of or are based upon any Violation, in each case to the extent (and only to
the extent) that such Violation occurs in reliance upon and in conformity with
written information furnished by such Holder expressly for use in connection
with such registration statement; and each such Holder will pay, as incurred,
any legal or other expenses reasonably incurred by any person intended to be
indemnified pursuant to this Section 1.7(b), in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this Section 1.7(b) shall not apply to
amounts paid in

<PAGE>

settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; provided, that in no event shall any
indemnification by a Holder under this Section 1.7(b) exceed the net proceeds
from the offering received by such Holder, except in the case of willful fraud
by such Holder.

            (c)   Procedures. Promptly after receipt by an indemnified party
under this Section 1.7 of notice of the commencement of any action (including
any governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 1.7,
deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if materially prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under
this Section 1.7, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.7. No indemnifying party,
in the defense of any such claim or litigation, shall, except with the consent
of each indemnified party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such indemnified party of a release from all
liability in respect to such claim or litigation. The indemnity agreements
contained in this Section 1.7 shall not apply to amounts paid in settlement of
any loss, claim, damage, liability or action if such settlement is effected
without the consent of the indemnifying party, such consent not to be
unreasonably withheld.

            (d)   Contribution. If the indemnification provided for in this
Section 1.7 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage or expense
referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of
the indemnifying party on the one hand and of the indemnified party on the other
in connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by a Holder
under this Section 1.7(d) exceed the net proceeds from the offering received by
such Holder, except in the case of willful fraud by such Holder. The relative
fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and
the parties' relative intent, knowledge, access to information, and opportunity
to correct or prevent such statement or omission.

<PAGE>

            (e)   Underwriting Agreement. Notwithstanding the foregoing, to the
extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.

            (f)   Survival. The obligations of the Company and Holders under
this Section 1.7 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise.

      1.8   REPORTS UNDER EXCHANGE ACT. With a view to making available to the
Holders the benefits of Rule 144 promulgated under the Securities Act and any
other rule or regulation of the SEC that may at any time permit a Holder to sell
securities of the Company to the public without registration, the Company agrees
to:

            (a)   make and keep public information available, in accordance with
SEC Rule 144, at all times after the effective date of the first registration
statement filed by the Company for the offering of its securities to the general
public so long as the Company remains subject to the periodic reporting
requirements under Sections 13 or 15(d) of the Exchange Act;

            (b)   file with the SEC in a timely manner all reports and other
documents as may be required of the Company under the Securities Act and the
Exchange Act; and

            (c)   furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144,
the Securities Act and the Exchange Act (at any time after it has become subject
to such reporting requirements), (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC which permits the
selling of any such securities without registration or pursuant to such form.

      1.9   ASSIGNMENT OF REGISTRATION RIGHTS. The rights to cause the Company
to register securities granted Holders under Section 1.2 may not be assigned to
a transferee or assignee of Registrable Shares without the prior written consent
of the Company, except that such rights may be freely transferred to any party
controlling, controlled by or under common control with a Holder without such
consent; provided, that the Company is provided with prompt notice of the name
and address of such transferee and such transferee agrees in writing to be bound
by the provisions of this Agreement.

      1.10  TERMINATION OF REGISTRATION RIGHTS. No Holder shall be entitled to
exercise any registration right provided for in this Section 1 after such time
as Rule 144(k) or another similar exemption under the Securities Act is
available for the sale of all of such Holder's shares without limitation as to
volume or manner of sale.

<PAGE>

2.    MISCELLANEOUS.

      2.1   ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
among the parties hereto pertaining to the subject matter hereof, and any and
all other written or oral agreements relating to the subject matter hereof
existing among any of the parties hereto are expressly canceled.

      2.2   RECAPITALIZATIONS, ETC. The provisions of this Agreement (including
any calculation of share ownership) shall apply, to the full extent set forth
herein with respect to the Registrable Securities and to the Common Stock, to
any and all shares of capital stock of the Company or any capital stock,
partnership or member units or any other security evidencing ownership interests
in any successor or assign of the Company (whether by merger, consolidation,
sale of assets or otherwise) that may be issued in respect of, in exchange for,
or in substitution of the Registrable Securities by reason of any stock
dividend, split, combination, recapitalization, liquidation, reclassification,
merger, consolidation or otherwise.

      2.3   SUCCESSORS AND ASSIGNS. Except as otherwise provided in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective permitted successors and assigns of the
parties. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and
assigns any rights, remedies, obligations, or liabilities under or by reason of
this Agreement, except as expressly provided in this Agreement.

      2.4   AMENDMENTS AND WAIVERS. Any term of this Agreement may be amended or
waived only with the written consent of the Company and the holders of at least
a majority of the Registrable Securities then outstanding. GPC and its
successors and assigns acknowledge that by operation of this Section 2.4, the
holders of at least a majority of the then outstanding Registrable Securities,
when acting together with the Company, will have the right and power to diminish
or eliminate any rights or increase any or all obligations under this Agreement.

      2.5   NOTICES. Any notice required or permitted by this Agreement shall be
in writing and shall be deemed sufficient upon delivery, when delivered
personally or by overnight courier or sent by electronic mail or fax, or
forty-eight (48) hours after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, addressed (a) if to the Company or
NeoTherapeutics, to 157 Technology Drive, Irvine, California 92618, Attention:
Chief Executive Officer or via facsimile to (949) 788-6706, with a copy to
Latham & Watkins, 650 Town Center Drive, Suite 2000, Costa Mesa, California
92626-1925, Attention: Alan W. Pettis, or via facsimile to (714) 755-8290, or
(b) if to GPC, to Fraunhoferstrasse 20, D-82152 Martinsried/Munich, Germany,
Attention: Chief Executive Officer or via facsimile to 49-89-8565-2610, with a
copy to Ropes & Gray, One International Place, Boston, Massachusetts 02110,
Attention: Marc A. Rubenstein, or via facsimile to (617) 951-7050.

      2.6   SEVERABILITY. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith. Until the parties have agreed upon an enforceable
replacement for such provision, (a) such provision shall be excluded from this
Agreement, (b) the balance of the Agreement shall be interpreted as if such
provision were so excluded and (c) the balance of the Agreement shall be
enforceable in accordance with its terms.

<PAGE>

      2.7   DELAYS OR OMISSIONS; REMEDIES CUMULATIVE. No delay or omission to
exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair
any such right, power or remedy of such non-breaching or non-defaulting party
nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any
waiver, permit, consent or approval of any kind or character on the part of any
party of any breach or default under this Agreement, or any waiver on the part
of any party of any provisions or conditions of this Agreement, must be in
writing and shall be effective only to the extent specifically set forth in such
writing. All remedies, either under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative.

      2.8   ATTORNEY'S FEES. If any action at law or in equity (including
arbitration) is necessary to enforce or interpret the terms of any this
Agreement, the prevailing party shall be entitled to reasonable attorney's fees,
costs and necessary disbursements in addition to any other relief to which such
party may be entitled.

      2.9   GOVERNING LAW. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by and
construed and enforced in accordance with the internal laws of the State of
California, without regard to the principles of conflicts of law thereof. The
Company and GPC hereby irrevocably submit to the exclusive jurisdiction of the
state and federal courts sitting in Orange County, California, for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, or that
such suit, action or proceeding is improper. Each of the Company and GPC hereby
irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by receiving a copy thereof sent
to the Company at the address in effect for notices to it under this instrument
and agrees that such service shall constitute good and sufficient service of
process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law.

      2.10  COUNTERPARTS. This Agreement may be executed in counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

      2.11  TITLES AND SUBTITLES. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

      2.12  AGGREGATION OF STOCK. All shares of Company stock held or acquired
by affiliated Persons (including former and current partners, former and current
members and former and current stockholders) shall be aggregated together for
the purpose of determining the availability of any rights under this Agreement.

<PAGE>

      2.13  CONFIDENTIALITY. Each Holder agrees that, except with the prior
written permission of the applicable party, it shall at all times keep
confidential and not divulge, furnish or make accessible to anyone any
confidential information, knowledge or data concerning or relating to the
business or financial affairs of the Company or any other party to which such
Holder has been or shall become privy by reason of this Agreement. The
provisions of this Section 2.13 shall be in addition to, and not in substitution
for, the provisions of any separate nondisclosure agreement executed by the
parties hereto with respect to the transactions contemplated hereby.

                            [Signature Page Follows]

      The parties have executed this Registration Rights Agreement as of the
date first above written.

NEOTHERAPEUTICS, INC.                     GPC BIOTECH AG

By: ______________________________        By: _______________________________

Name: ____________________________        Name: _____________________________

Title: ___________________________        Title: ____________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]